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Abstract 
 
DAX-1, an orphan nuclear hormone receptor, acts mainly as a repressor 
through transcriptional protein complexes. Its unique structure and specific 
expression raises questions as to what its precise interactions are and how it 
mediates its repressive function. While it is known to play a role in sexual 
development and adrenal insufficiency, expression in certain types of cancer 
suggests additional functions and interactions. Knock in of DAX-1 into a low-DAX-1 
expressing cancer cell line has been previously observed to increase apoptosis, 
while, inversely, down in a high-DAX-1 expressing cancer cell line shows a decrease 
in apoptosis. Target genes that belong to the TNFα and BCL-2 families have shown 
changes in expression correlating to the modified levels of DAX-1 in knock-down 
experiments. Direct regulation of BCL-2, one of the target genes of interest, was 
investigated further based on mirrored expression changes of DAX-1 in knock-down 
and knock in experiments through ChIP experiments. These findings emphasize a 
significant role of DAX-1 in moderating apoptosis in a breast cancer cell line. 
In the context of undifferentiated mouse embryonic stem cells, Dax-1 is 
highly expressed and has been shown to be an important contributor to the 
pluripotent state.  Potential downstream targets of Dax-1 were previously identified 
based on significant changes in expression when Dax-1 expression was down 
regulated.  Two methods, siRNA and CRISPR-Cas9, were used to decrease Dax-1 
expression in the E14 mouse embryonic stem cell line.  Direct interactions and other 
novel stem cell factors were confirmed using analysis of publically available ChiP-
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seq data.  Ultimately, while Dax-1 is not a master regulator, its transcriptional 
control of specific genes that are key in the maintenance of pluripotency is an 
important component of stem cell growth and differentiation. Bioinformatic analysis 
of ChIP-seq experiments brought to light general patterns as to how Dax-1 
contributes to pluripotency, and additional ontologies of Dax-1 target genes for 
future studies. 
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Chapter 1 
Nuclear Hormone Receptors and DAX-1  
Introduction 
Nuclear hormone receptors (NHRs) are a superfamily of eukaryotic 
transcription factors that are involved in the regulation of specific target genes for 
various biological processes through the response to hormones and other metabolic 
ligands [1]. These various proteins share a conserved general domain structure, as 
illustrated in Figure 1-1A: an N-terminal domain (A/B), a DNA binding domain, or 
DBD (C), a flexible hinge region (D), a ligand binding domain, or LBD (E), and a C-
terminal domain (F). There are seven subfamilies, identified as NR0 through NR6, 
based on sequence similarity in the conserved DBD and LBD regions of the genes 
[2]. This sub-categorization helps dictate the gene nomenclature rules.  
These proteins generally have an effect on gene transcription upon binding 
of a ligand [3].  In general, once these transcription factors bind ligand and are 
activated, they can bind to specific sequences, also known as hormone response 
elements (HREs), present within the regulator regions of target genes. Typically, 
NHRs carry out their activity by forming dimers on these response element 
sequences. The combination of NHRs may either be as homodimers, composed of 
two identical receptors, or as heterodimers, composed of different receptors [4]. 
NHRs that act as activators or coactivators contain LxxLL (Leu-x-x-Leu-Leu) 
motifs in their primary amino acid sequence, which manifest as alpha helices in the 
protein structure. Also known as NR boxes, the sequence allows for protein-protein 
interactions, and therefore the formation of transcriptional factor complexes [5, 6]. 
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In contrast, NHRs that generally act as repressors or corepressors have a consensus 
motif known as a CoRNR box, consisting of an Lxx H/I xxx I/L motif that is 
manifested as an extended helix, and interacts with similar residues such as the 
LxxLL motif. The variance in the length of the helical interface allows for a difference 
in the transcription factor complexes [7]. 
In humans, there have been 48 different NHRs identified to date. Mice, with 
47 known NHRs, share a similar number of this group of proteins encoded in their 
genome. This conservation of nuclear receptors is reflected in only members of the 
animal kingdom [8], and is not observed in any other relatives of metazoans [9]. 
NHRs have been studied in great detail in numerous model systems because of their 
involvement with key signaling pathways and the potential for targeting in diseases.  
 Proteins within the NHR family can be further categorized into three groups: 
steroid hormone receptors, non-steroid hormone receptors, and orphan receptors. 
Steroid hormone receptors respond to steroids, while non-steroid hormone 
receptors interact with other ligands such as thyroid hormone, retinoic acid, and 
vitamin D2. Lastly, the remaining NHRs that have no known ligand interaction are 
classified as orphan nuclear hormone receptors. [10] 
DAX-1 is a unique orphan nuclear hormone receptor that is encoded by the 
NR0B1 gene. The protein name stands for dosage sensitive sex reversal, adrenal 
hypoplasia congenital on the X chromosome, gene 1; for humans, it is written out as 
DAX-1, while for mice it is noted as Dax-1 [11].  The protein product of the human 
NR0B1 gene is 470 amino acids, pieced together from two exons.  In contrast to the 
typical NHR structure, the DAX-1 protein has a repetitive domain consisting of 3.5 
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alanine/glycine rich repeats that each are about 65 to 70 amino acids long in place 
of the DNA binding domain, as shown in Figure 1-1B.  It shares this unusual domain 
with a close cousin within the NHR family called SHP (small heterodimer partner), 
encoded by the NR0B2 gene [12] [13]. 
While the ligand-binding domain is conserved, DAX-1 is identified as an 
orphan due to no known ligand interaction. The lack of the DNA binding domain, no 
known ligand interaction, and LxxLL sites strongly implies that DAX-1 primarily 
functions within the cell through interactions with other proteins, such as Wilm’s 
tumor 1 (WT1) and steroidogenic factor 1 (SF-1) [14] rather than direct binding to 
DNA as a transcriptional factor. And despite having LxxLL sites, which is typical of 
coactivators, DAX-1 has been shown to act as a corepressor [15]. X-ray 
crystallographic data has provided some insight as to how DAX-1 mediates its 
repressive function through binding directly to other NHR proteins. The entire 
protein has yet to be isolated and crystallized, but the LBD region of DAX-1 has been 
successfully crystallized in complex with the protein LRH-1, as illustrated in Figure 
1-2. The site of interaction with LRH-1 is at an extended surface, therefore occluding 
binding of other co-activators to LRH-1 [16]. This type of protein-protein interaction 
is a likely explanation of why DAX-1 is a strong transcriptional repressor. 
The original discovery of DAX-1 was through duplications in the gene that 
caused males to phenotypically appear female, corresponding to the “dosage-
sensitive sex reversal” portion of the name [17]. Additional research found that 
mutations within the same gene led to X-linked adrenal hypoplasia congenital 
(AHC), an uncommon disorder of adrenal gland development [18]. Outside of these 
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diseases, DAX-1 has a restricted expression pattern. It is highly expressed in stem 
cells before differentiation, and is noted to contribute to early embryogenesis [11]. 
In an adult organism, expression is limited to select steroidogenic organs, especially 
within the hypothalamus-pituitary-adrenalgonadal axis [19].  
More recently, there has been a proposed role of DAX-1 in various cancers, in 
addition to its role in normal cells. Numerous NHRs have been linked to the 
pathogenesis and treatment of various cancers [20], and DAX-1 is no exception. Its 
strong influence on pluripotency, a characteristic seen also in a subset of cancer 
cells, and unusual structure brought DAX-1 into the spotlight as a candidate for 
cancer therapy [21].  In this thesis, we study the specific molecular mechanisms and 
interactions by which Dax-1 functions within mouse ES cells and human DAX-1’s 
influence on processes within normal and breast cancer cells.  
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A.  
 
 
B. 
 
Figure 1-1. Functional domain structures of a general nuclear hormone 
receptor and DAX-1. A. The general nuclear hormone receptor gene regions with 
the following labeled structures: an N-terminal domain (A/B), a DNA binding 
domain, or DBD (C), a hinge region (D), a ligand binding domain (E), and a C-
terminal domain (F), and B. the DAX-1 protein structure, with the 3.5 
alanine/glycine rich repeats on the N-terminal end (R) and a conserved LBD-like 
domain (E).  
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Figure 1-2. X-Ray crystallography illustration of mouse Dax-1 ligand binding 
domain.  Structure is based on the available image of Dax-1 in complex with LRH-1 
(Fletterick Group, pdb file 3F5C). The chains are colored from blue to red, in the 
direction of the N-terminus to C-terminus. Figure generated by P. Foster.  
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Chapter 2 
Manipulation of DAX-1 Expression in a Range of Model Systems 
Introduction 
As previously mentioned, DAX-1 expression is restricted to stem cells and a 
number of organs within a mature organism. The research detailed in this thesis 
examines the role of DAX-1 in human breast cancer cells as well as mouse 
embryonic stem cells. Both these research projects required a means to study and 
manipulate DAX-1 expression in order to explore the outcome of this change. For 
these experiments, the human cell lines MCF7 (epithelial breast cancer cells) and 
MCF10A (mammary epithelial cells) and the mouse embryonic stem cell line E14 
were used. MCF7 cells are typically used as a triple positive cell culture model, 
because these cells express estrogen receptor, progesterone receptor, and HER2 
[22]. Transient transfection assays were used to exogenously express DAX-1 in the 
cell types with little to no DAX-1 expression, while RNAi and CRISPR methods were 
utilized to reduce or eliminate DAX-1 expression in cell lines with endogenous 
expression of DAX-1. Once these models had been established, we could explore the 
outcome of changes in DAX-1 expression in both human cancer cells (Chapter 3) and 
mouse embryonic stem cells (Chapter 4). 
 
pcDNA expression vector 
In order to introduce DAX-1 into the MCF7 cells, an expression plasmid 
containing the entire human DAX-1 coding sequence was utilized. The expression 
vector used for these experiments was pcDNA3.1, which contains unique restriction 
 20 
enzyme target sites in both directions for sequence insertion (Figure 2-1). Other key 
features of the plasmid include the genes for ampicillin and neomycin resistance, 
which aid in the selection process after transformation into competent E. coli. The 
entire human DAX-1 coding sequence was amplified by PCR and cloned into the 
plasmid using the BamHI and XhoI restriction enzyme sites. Confirmation of correct 
insertion of DAX-1 into pcDNA3.1 was confirmed by DNA sequencing. This 
expression plasmid was previously generated by C. Tzagarakis-Foster. 
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Figure 2-1. pcDNA3.1 vector (Life Technologies) utilized in transient 
transfection assays. 
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RNA interference 
 RNA interference is a gene silencing technique that utilizes non-coding RNAs 
to target messenger RNA present in an organism and affect gene expression before 
translation into protein [23].  Numerous forms of RNA can be utilized, ranging from 
double stranded RNA to short hairpin RNA, with different structures and stability.  
While this phenomenon is conserved across most complex organisms, it was not 
exploited until the discovery of sequence-specific short interfering RNAs (siRNAs).  
These are 21 nucleotide long sequences, with 19 of those nucleotides specific to the 
target sequence to form a duplex, and the remaining 2 unpaired at the 3’ ends [24]. 
The pathway of RNA interference, illustrated in Figure 2-2, starts in the 
cytoplasm when Dicer, an RNAse III endonuclease, processes siRNA precursors such 
as dsRNA or shRNAs. Certain kinds of optimized techniques in research skip this 
processing step and may allow for the transfection of the shortened siRNA from the 
start. A “mature” siRNA molecule then enters into a multi-protein RNA-induced 
silencing complex, or RISC.  The completed complex pairs the siRNA with the target 
mRNA at the complementary region, and the protein Argonaut-2 (Ago2) mediates 
the cleavage of the siRNA-mRNA pair within the complex. Other notable proteins 
involved in RISC include a transactivating response RNA-binding protein, or TRBP, 
that helps facilitate the transfer of Dicer-generated fragments to Ago2 for RNA 
degradation. While there are cleavage independent mechanisms to block translation 
of the targeted mRNA, the formation of the complex allows for the target to be 
broken up several times. The resulting smaller RNA fragments are ultimately 
degraded by exoribonucleases, and the loss of the targeted mRNA in the cell reduces 
 23 
the amount of protein produced from translation [25]. This technique is widely used 
in research for many model organisms, and was applied to both the MCF7 human 
breast cancer cells and the E14 mouse embryonic stem cells in experiments to 
knock-down endogenous DAX-1 expression.  
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Figure 2-2.  RNA interference mechanism. Starting materials range from short-
hairpin RNA (shRNA) or double stranded RNA (dsRNA) that is then matured into a 
simplified form of single stranded RNA, or initially short interfering RNA (siRNA) 
that is already shortened to a length of twenty to thirty base pairs long. Once a 
target messenger RNA is found through a section complementary to the siRNA, RISC 
is formed to capture and degrade the mRNA, resulting in a loss of gene expression at 
the RNA level. 
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CRISPR-Cas 
 A recent technique utilizing an endogenous mechanism called CRISPR-Cas 
has been propelled as a more permanent modification to protein expression.  The 
name is short for “clustered regularly interspaced short palindromic repeats – 
CRISPR associated proteins.”  In contrast to commonly used techniques, such as 
RNAi that targets a gene at the RNA level in order to reduce its expression, CRISPR 
affects cell functions through genomic editing [26].  
The technique was developed based on microbial immune systems, where 
RNA-guided endonucleases can interact with specific targets, typically exogenous 
DNA from viruses or other bacteria, and allows the organism to both eliminate the 
invading genomic information as well as acquire immunity against similar viruses 
and plasmids [27]. Optimized plasmids have been developed to contain core 
elements of the CRISPR-Cas system, selection genes for transformation and cloning, 
and specific restriction enzymes sites for the insertion of a target guide sequence. 
One of the main elements of the most commonly used optimized system is 
Cas9, part of the Cas protein family. This family, whose name is short for “CRISPR-
associated genes,” consists of microbial endonucleases than can utilize short RNA 
sequences as guides to cause damage to genomic DNA [28].  Cas9 is specifically used 
for research applications because while other systems may require a complex of 
multiple Cas proteins, Cas9 is large protein that alone is sufficient for generating a 
mature guide RNA and cleaving the target DNA [29]. 
The endonuclease can only act on a target DNA by using a guide sequence, 
often referred to as CRISPR repeat-spacer RNA, or crRNA. This fragment contains 
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conserved repeat fragments and a variable spacer sequence that is complementary 
to a target region [30]. While the length of this sequence varies in size depending on 
the type of Cas protein used, the Cas9 protein is able to create and use a guide with a 
target sequence as short as 21 nucleotides long.  Together with a trans-activating 
crRNA (tracrRNA), an RNA duplex is formed and matured to form a hybrid, acting as 
a complete guide for Cas9 [31].  This allows for Cas9 to situate itself at the target 
location with base-pair matching of the guide RNA and cause DNA damage (Figure 
2-3). 
The damage caused by the Cas9 endonuclease is a double-stranded break 
that can be repaired in two ways.  Nonhomologous end joining, or NHEJ, is an 
imprecise type of repair that through immediate ligation to close the break 
introduces insertion and deletion (or indel) mutations that vary in length [32]. 
When applied to damage within a gene, this disrupts the translational reading 
frame; if applied in a noncoding region, this can potentially disrupt a binding site of 
transcriptional factors.  Another type of DNA repair is homology-directed repair, or 
HDR, which utilizes a template to repair the site of damage. Through the use of the 
of a donor template, more precise point mutations or insertions can occur at the site 
of damage [33].  
Additional genomic engineering applications of the Cas9-based technique can 
result in sequence specific insertions, large deletions, genomic rearrangements 
through inversions or translocations, gene activations, epigenetic modification, or 
tagging of genomic loci [34]. Applications of this technique include early treatment 
in haploid cells to increase the frequency of successful gene modification without 
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selection [35], in human pluripotent stem cells [36], and even in entire living 
organisms [37]. CRISPR-Cas9 is also applicable to affect multiple gene targets with 
the inclusion of several guide sequences within the optimized plasmid [38], further 
expanding the applications while maintaining the simplicity of the system. In the 
context of this thesis, CRISPR-Cas9 was applied to target the coding sequence of 
mouse Dax-1 at multiple locations through the design of several guide sequences. 
The sequences were used individually in CRISPR-Cas9 transfection and cells were 
selected for proper Dax-1 deletion before further analysis in Chapter 4. 
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A.  
 
B. 
 
Figure 2-3. CRISPR-Cas9 knock-down mechanism. A. A complete CRISPR-Cas9 
plasmid includes a sequence for the Cas9 endonuclease, an inserted guide sequence, 
and selection genes. The plasmid is transfected into cells or an organism and allows 
for internal production of the key CRISPR system elements. The ribonucleic-protein 
complex of Cas9 with a mature guide allows for DNA damage at a target site. This 
damage can be repaired by either NHEJ or HDR DNA repair mechanisms. B. Based 
on the type of repair and Cas9 used, there are a number of different outcomes to 
CRISPR modifications. Without a provided template, the site of damage can be 
repaired through non-homology end joining and result in random insertions and 
deletions at the target site. With a template, homology directed repair allows for 
either the insertion of a provided sequence or an inversion of the targeted section. 
Deactivation of Cas9 can eliminate the endonuclease aspect and allow for guide 
direct tagging or modification without damage to the genome. 
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Methods 
Cell Culture 
MCF7 epithelial breast cancer cells were obtained from American Type 
Culture Collection.  The cells were cultured and passaged in a 5% carbon 
dioxide tissue culture incubator at 37°C. Cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) with L-glutamine and without phenol red, 
supplemented with 10% charcoal-stripped fetal bovine serum (American 
Type Culture Collection, treated with dextran coated charcoal from Sigma-
Aldrich) and 1% penicillin/streptomycin (Gibco). 
MCF10A human mammary epithelial cells were obtained from American 
Type Culture Collection. The cells were cultured in the same incubator 
conditions as MCF7 cells. Complete MCF10A media used Dulbecco’s Modified 
Eagle Medium (DMEM) with phenol red and additional supplements of 10% 
fetal bovine serum (American Type Culture Collection), 1% 
penicillin/streptomycin (Gibco), 100 ng/mL of cholera toxin (Sigma-Aldrich), 
and mammary epithelial growth medium (MEGM) SingleQuot additives 
[hydrocortisone (05 μg/mL, human EGF (10ng/mL), insulin (10 μg/mL)] 
(Lonza Corporation).  
The E14 mouse embryonic stem cell line was donated from the lab of Dr. 
Mohammed El Majdoubi, from Dominican University of California in San 
Rafael, CA.  The feeder-free cells were cultured and passaged in a 5% carbon 
dioxide tissue culture incubator at 37°C in 0.1% gelatin-coated flasks. The 
media used for the cultured cells was Dulbecco’s Modified Eagle Medium 
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(DMEM) with phenol red, GlutaMax, and 4.5 g/L D-glucose.  For the complete 
media, additional supplements of 15% fetal bovine serum (American Type 
Culture Collection), 1% penicillin/streptomycin (Gibco), 1% non-essential 
amino acids (Gibco), 1,000 U/mL Leukemia Inhibitory Factor (Sigma-
Aldrich), and 0.1mM β-mercaptoethanol (Promega) were added through a 
sterile filter. This combination is modified from those outlined by the Cho 
Lab [39]. 
To passage cells, flasks were washed with phosphate buffered saline (PBS) 
and treated with Trypsin-EDTA (0.05%) with phenol red (Gibco) at 37°C 
until cells lifted from the flask. Cells were then re-suspended and passaged, 
ranging from 1:5 to a 1:10 ratio.  
 
DAX1 knock-in into MCF7 cells 
A pcDNA3.1-DAX1 construct was provided by Dr. Christina Tzagarakis-
Foster, and transfected into the MCF7 cells using Lafectine RU50 according to 
protocol, using 50uL for every μg of plasmid.  Treated cells were initially 
seeded in “low” media, composed of DMEM without phenol red 
supplemented with 1% fetal bovine serum, for up to 24 hours before 
treatment in complete media. Cells were treated for 48 hours before 
collection. Samples collected from treated cells are referred to herein as 
“MCF7+DAX-1”. 
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DAX1 knock-down in MCF10A and E14 cells with siRNA 
A set of three synthetic double stranded stealth siRNA oligonucleotides 
designed to target the human DAX-1 gene were obtained from Life 
Technologies. The three siRNAs, which targeted human DAX-1 in different 
regions of the gene, were used for transfection into MCF10A cells, as shown 
in Table 2-1.  Three synthetic Silencer pre-designed small interfering RNA 
(siRNA) oligonucleotides targeting mouse Nr0b1 (Life Technologies) were 
utilized for Dax-1 knock-down, with sequences and targeting sites listed in 
Table 2-2. Ambion Silencer Negative Control #1 was used as the non-
targeting siRNA sample. Six-well plates were seeded with 500,000 MCF10A 
cells per well in complete media and reverse transfected using Lafectine 
RU50 (MednaBio). The total concentration of the siRNA for MCF10A cells was 
300pmol for each well, while two concentrations of 20pmol and 80pmol of 
each individual siRNA was used for the mouse embryonic stem cells. Mouse 
cells were treated a second time with a change of media after 24 hours. 
Collections for mRNA and protein lysate analysis were carried out after 48 
hours. 
 
Statistical Anaylsis 
Data from the qPCR analysis are presented with the mean + standard 
deviation of triplicate experiments, normalized using GAPDH Cq values. 
Statistical significance is calculated using the two-tailed t-test formula built 
into Microsoft Excel. A single asterisk (*) represents samples that were 
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p<0.05, a double asterisk (**) represents samples that were p<0.005, and a 
triple asterisk (***) represents samples that were p<0.001.  
 
Table 2-1. siRNA sequences for MCF10A treatment.  
siRNA Sequence Target Region 
hDAX-1 siRNA 1 CCCAUGACAGAUUCAUCGAACUUAA 
UUAAGUUCGAUGAAUCUGUCAUGGG 
Exon 2 
Position 1290 
hDAX-1 siRNA 2 CCCAUGACAGAUUCAUCGAACUUAA 
UUAAGUUCGAUGAAUCUGUCAUGGG 
Exon 2 
Position 1383 
hDAX-1 siRNA 3 CAGUGGCAGGGCAGCAUCCUCUACA 
UGUAGAGGAUGCUGCCCUGCCACUG 
Exon 1 
Position 44 
 
Table 2-2. siRNA sequences for mESC treatment. Sequences were not made 
available with purchase. 
siRNA Target Region 
mDax-1 siRNA 1 Exon 1, Position 981 
mDax-1 siRNA 2 Exon 1, Position 1187 
mDax-1 siRNA 3 Exon 1, Position 987 
 
 
CRISPR-mediated knock-down in E14 mESC 
pSpCas9(BB)-2A-Puro (PX459) plasmid was purchased from Addgene 
(plasmid # 48139).  The structure of the plasmid along with key features is 
illustrated in Figure 2-4. Oligonucleotides for insertion into the CRISPR-Cas9 
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vector backbone to target mouse DAX1 were designed using the online 
CRISPR Design web program (http://crispr.mit.edu/).  Target areas for each 
guide are shown in Figures 2-5 and 2-6, with sense and antisense sequences 
listed in Table 2-3. Annealed oligonucleotides were inserted into the pX459 
plasmid using BbsI as the restriction enzyme to cut the insertion site and T4 
DNA ligase (New England Biolabs).  Proper insertion of the guide sequences 
into the plasmid backbone was verified through both a BbsI/AgeI double 
digest, based on the restriction enzyme target sites illustrated in Figure 2-4B, 
as well as DNA sequencing using a U6 primer (MCLAB, Molecular Cloning 
Laboratories). Modified plasmids with successful insertions were 
transformed into competent DH5 E. coli (New England Biolabs) and plasmid 
DNA was extracted using the Plasmid Plus Maxi kit (Qiagen).  Complete 
pX459 with oligonucleotide insertions were transfected into mESCs using 
Lafectine RU50 1000ng/μL according to the product protocol using reduced 
media (Dulbecco’s Modified Eagle Medium (DMEM) with phenol red; 10% 
FBS, LIF, β-mercaptoethanol).  Cells were treated for 48 hours before 
selection with 1.0 μg puromycin. Treatment with puromyin was sustained for 
48 hours before surviving cells were collected and recovered in normal 
media. Individual colonies were picked in parallel to grow out individual 
transfected cells and obtain clonal populations for further analysis [40]. 
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A.
 
B. 
 
Figure 2-4. Structure summary of the CRISPR-Cas9 optimized plasmid pX459.  
A. Overall pX459 structure provided by Addgene. B.  Details of BbsI restriction 
enzyme sites for insertion of a designed guide sequence for CRISPR-Cas9 targeting. 
Figure provided by Zhang lab. 
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Table 2-3. Sense and anti-sense sequences for oligonucleotides constructed 
using the online CRISPR Design web program to target the Dax-1 gene. 
Guid
e 
Nam
e 
Sense Anti-sense Targ
et 
Exon 
Color 
Code 
G3 caccGGGTGAGGACCACCCGT
GGC 
aaacGCCACGGGTGGTCCTCA
CCC 
Exon 
1 
green 
G6 caccGCTGAGATTCATCAATA
GCG 
aaacCGCTATTGATGAATCTC
AGC 
Exon 
2 
pink 
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agtttataaagctgtcatagaaatggactttttgccatttaagcatttctttccccaataaaggaaataagttagaggtcaga
gtctaagttaatggcaagagttggaacagagccctaactagctgcctggggttcactgctagctcttctcttccccaggtag
aggcaggaggggtggagtgaagaaggaaaggtggtatgtggtatgctagttccagtgctgagactctcccttggatttcc
agcttctagggagtgtttgcccctttgagctttcgaggtcatggccacacacattcaagcacaaaggcgcgtccccctctgc
gcccttgtccaagaggaggaggcggacgcgcttgcgtgcgcattcagtataaataagtcccaagcggcggccactgggc
AGAACGAGCTACAGGAGCCTCAGGCCATGGCGGGTGAGGACCACCCGTGGCAGGGCAG
CATCCTCTACAATCTACTGATGAGCGCGAAGCAGAAGCACGCGTCTCAGGAAGAGCG
AGAGGTGCGCTTGGGGGCTCAGTGCTGGGGTTGCGCCTGCGGTGCTCAGCCCGTCCT
GGGTGGGGAGAGACTGTCCGGCGGGCAAGCCAGGTCCCTCTTGTACCGCTGCTGCTT
TTGTGGGGAGAATCACCCGCGCCAGGGTGGCATCCTCTACTCTATGCTCACCAACGC
CAGGCAGCCAAGCGTGGCGACCCAGGCGCCGAGGGCACGATTCGGAGCACCTTGCTG
GGGCTGCGCCTGCGGCAGCGCAGAGCCCCTGGTGGGCAGAGAGGGGCTGCCGGCTGG
CCAGGCCCCCTCGCTCCTGTACCGCTGCTGCTTCTGCGGAGAAGAGCACCCGAGGCAG
GGCAGCATCTTATACAGCTTGCTCACTAGCGCTCAGCAAACGCACGTGTCTCGGGAA
GCACCCGAGGCACATCGCAGAGGCGAGTGGTGGCAGCTGTCCTACTGTACCCAGAGT
GTGGGTGGCCCAGAGGGGCTGCAGAGCACACAGGCCATGGCGTTCCTGTACCGCAGC
TATGTGTGCGGTGAAGAGCAGCCCCAGCAGATCAGCGTTGCCTCTGGCACGCCCGTG
AGCGCAGACCAAACACCAGCGACCCCGCAAGAGCAGCCGAGGGCTCCCTGGTGGGAC
GCCTCACCTGGTGTGCAGCGTCTGATCACACTCAAGGATCCACAGGTGGTGTGCGAG
GCAGCGTCCGCTGGCCTGTTGAAGACCCTGCGCTTTGTCAAGTACTTGCCCTGCTTCC
AGATCCTGCCCCTAGATCAGCAGCTGGTGCTGGTGCGGAGCTGTTGGGCGCCCCTAC
TCATGCTTGAGTTGGCCCAAGATCACCTGCACTTCGAGATGATGGAGATCCCGGAGA
CCAACACGACGCAGGAAATGCTTACCACCAGGCGGCAGGAGACCGAAGGTCCAGAGC
CTGCAGAGCCCCAGGCCACAGAGCAGCCACAGATGGTGTCCGCGGAGGCTGGGCACT
TGCTCCCAGCTGCTGCGGTCCAGGCCATCAAGAGTTTCTTTTTCAAGTGCTGGAGTC
TGAACATTGACACCAAAGAGTATGCCTATCTGAAAGGGACCGTGCTCTTTAACCCAG
gtaagcattgtcaaccttgtgcactgtctcttcaggtcagaaaagcaccactacagacatttatgagtttttagtaggggttt
tggagcccacttgactgtgactgactctgcaaatctgctgcacacatcaggaataccctgtcaagtggtcaaatgggtgag
cttctgccagaaacttggcactggattggtggtgatagtgtgtgtgtgtggggggggggggggcaggggttggggggag
ggtggggaacgaaccagtaagctttgtacctggctctctattatctgctgctacagaagtttctgtcttcataggacctggct
aactcttc 
 
 
Figure 2-5. CRISPR targets within the Dax-1 gene (first exon).  Sequence of the 
first exon of the Dax-1 gene, with CRISPR targets for guide 3, highlighted green and 
underlined. Intron/non-coding nucleotides are in lowercase, and exon/coding 
regions are in uppercase.   
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tattaagtgtgccagtgtttgtgcacactttagtgtgtccagtgtatgtgcacacatcctttcatccttagaagtgttgcttctg
aaaacttagaacttatttcagtccattattttaggccccagaaaacccttttaatcaagaagctagggttctttttaatcggg
atgggactaaaaaaaatgagtttggcctaaaccataaagatcctgtggtgagctgttttaaaataaagttttctcctttcag
ACCTGCCTGGCCTGCAGTGCGTGAAATACATTGAGGGTCTTCAGTGGAGAACCCAGC
AGATCCTTACTGAGCACATCCGGATGATGCAGAGAGAGTACCAGATCAGATCCGCTG
AACTGAACAGTGCCCTTTTCCTGCTGAGATTCATCAATAGCGATGTCGTCACTGAACT
CTTTTTCAGGCCCATCATTGGTGCAGTCAGCATGGATGATATGATGCTGGAGATGCT
CTGTGCAAAGCTGTGAAGGCATATGTCCACTCAAGTGCATTTTACTATAGATGGAG
AAAGCGGTCGTAGCTGTAGGCAGAAGAGTGCTAAAATTTGTGAAACCAAACTTTCT
TGTATTTTTACATGCATAGTATATTTGTATTCAATTGAAGAAATACTTTAGTTACA
ATGTAAAAATCCCTCTGCTCCATACTGGCTTCTTGTGAAGGAAAGCATTTGCAAACA
AATCACTATTTCTGTATATCTCTAAGAGTGTGGTACTAGGCTAACAAGCTAATTTC
ATAAAAATAACATCTCTTTCCATTAACCCCGCCAAATAAAATTTATAATATTAACTT
TTAATAAAATTTAAGGTACTAACCGTTaaacggactggagagttttcttggggtttacagcttcaaata
ctttcaaatctagctaaaataactgaagatacaatcgtgagtaacttcatggaatttaatgctacagtatgtcactggttaa
aaaaaaaaaaaggttattttgcctggcttcactgcttccattaacagtataaaagattgtcttcattcctgcctggaactcaa 
 
 
Figure 2-6. CRISPR targets within the Dax-1 gene (second exon).  Sequence of the 
second exon of the DAX1 gene, with the target for guide 6 (G6) underlined, in italics, 
and in pink. Intron/non-coding nucleotides are in lowercase, and exon/coding 
regions are in uppercase.   
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Results 
MCF7 breast cancer cells were successfully treated to express DAX-1, as 
verified by both standard PCR run through an agarose gel (Figure 2-7A) and 
quantitative PCR analysis (Figure 2-7B). Knock-in expression was nearly four times 
the relative untreated expression when normalized with GAPDH using delta Cq 
calculations, and was considered to be statistically significant with a p-value less 
then 0.001.  These samples were used for further analysis in Chapter 3. 
 MCF10A cells experienced a reduction in DAX-1 mRNA expression with 
siRNA treatment using the three transcripts listed in Table 2-1, as verified by 
standard PCR in agarose gel (Figure 2-8A) and quantitative PCR (Figure 2-8B). 
Relative expression was reduced to negligible amounts through delta Cq 
calculations and was statistically significant with a p-value of less than 0.005. These 
samples were used for further analysis in Chapter 3. 
 Mouse embryonic stem cells were treated with both siRNA and CRISPR-Cas9 
methods to knock-down endogenous expression of Dax-1. The transient knock-
down of Dax-1 expression using siRNA transcripts listed in Table 2-2 was verified 
through agarose gel electrophoresis of standard PCR samples (Figure 2-9A), 
quantitative PCR analysis (Figure 2-9B), and western blotting (Figure 2-9C). Using 
two concentrations of siRNA treatment, the cells treated with 20 pmol and 80 pmol 
of siRNA each experienced a knock-down to half the normal expression when 
compared to untreated and Scramble/negative control (NC) cells. Both values were 
statistically significant when compared to the untreated and negative control, with 
the 20 pmol sample having a p-value of less than 0.005 and the 80 pmol sample 
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having a p-value less than 0.001.  These samples were used for further analysis in 
Chapter 4. 
 Development of a pX459 plasmid complete with an inserted guide for Dax-1 
CRISPR-Cas9 knock-down in mESC is shown in Figure 2-10. Based on the design of 
the insertion site (Figure 2-4B), successful insertion of a guide sequence results in 
the loss of the BbsI restriction enzyme target site. Comparison of a complete 
plasmid with insertion and one with no insertion is shown in Figure 2-10A. Loss of 
the BbsI site results in a single linear product when digested with both BbsI and 
AgeI.  However, lack of an insertion preserves the BbsI site resulting in two 
fragments, including a 1,000 base pair fragment (detectable in Figure 2-10A).  
 Initially, the six guides, illustrated in Figures 2-5 and 2-6 and listed in Table 
2-3, were screened for proper insertion. Out of the six, guide 3 and 6 passed the 
double digest screen and showed no 1kb dropout fragment, and were subsequently 
verified by DNA sequence analysis (Figure2-10A and B). Following transfection with 
the verified plasmids and puromycin screening, several individual mESC colonies 
that survived treatment were isolated. Whole flask samples (labeled with the letter 
A) and isolated colonies (labeled from 1 to 10) were used for further Dax-1 knock-
down verification from the two treatments of G3 and G6 CRISPR-Cas9 guides that 
were selected for. These were tested using standard PCR in agarose gel (Figure 2-
11A), quantitative PCR (Figure 2-11B), and western blots (Figure 2-11C). Based on 
the results, isolates G3-1 and G6-1 were used for further analysis in Chapter 4. 
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A.            B. 
     
 
Figure 2-7. Introduction of DAX-1 expression in MCF7 cells by transient 
transfection with pCDNA DAX-1. A. Agarose gel electrophoresis of PCR samples 
comparing DAX-1 expression in untreated and transfected samples (GAPDH is 
shown as a positive control).  B. qPCR results comparing the relative expression of 
DAX-1 mRNA in untreated and transfected cells. Error bars on qPCR results 
represent standard deviation of the mean. 
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A.            B. 
                       
Figure 2-8. siRNA DAX-1 knock-down in MCF10A. A. Agarose gel electrophoresis 
of PCR samples comparing DAX-1 amounts in untreated and transfected samples 
(GAPDH is shown as a positive control).  B. qPCR results comparing the relative 
expression of DAX-1 mRNA in untreated and transfected cells. Error bars on qPCR 
results represent standard deviation of the mean. 
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A.     B. 
    
 
C.  
 
Figure 2-9. siRNA Dax-1 knock-down in mESC. A. Agarose gel electrophoresis of 
PCR samples comparing Dax-1 amounts in untreated and transfected samples 
(GAPDH is shown as a positive control).  B. qPCR results comparing the relative 
expression of Dax-1 mRNA in untreated and transfected cells. Error bars on qPCR 
results represent standard deviation of the mean. C. Western blot of Dax-1 protein 
expression in untreated and transfected mESC. GAPDH protein expression is 
included as a loading control. 
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A.  
 
B.  
 
C.  
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Figure 2-10. Dax-1 specific CRISPR-Cas9 construct design. A. Screen cloned 
samples for proper insertion through a double digest with restriction enzymes AgeI 
and BbsI. The guide insertion site has BbsI target sites, so without an insert, a 
double digest will show a 1kb fragment. With guide sequence insertion, loss of the 
BbsI target site will lead to a single cut at the AgeI site and result in a linear product 
around 9kb length. B. Sequencing results verifying guide sequence insertion 
(highlighted in grey) in a guide 3 sample. C. Sequencing results verifying guide 
sequence insertion (highlighted in grey) in a guide 6 sample. 
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A.  
 
B.  
 
C.  
 
 
Figure 2-11. CRISPR Dax-1 knock-down in mESC. A. Agarose gel of PCR samples 
comparing Dax-1 amounts in untreated and treated G3 and G6 samples (guide 
targets illustrated in Figure 2-5 and 2-6) with GAPDH as a positive control, B. qPCR 
results comparing the relative expression of Dax-1 mRNA in untreated and G3 and 
G6 transfected cells. Error bars on qPCR results represent standard deviation of the 
mean. C. Western blot analysis of Dax-1 protein expression in untreated and G3 and 
G6 transfected cells. GAPDH is included as a loading control. 
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Discussion 
The successful treatment of the human cell lines MCF7, with the introduction of 
DAX-1 expression through a pcDNA3.1 vector, and MCF10A , with the knock-down 
of DAX-1 expression through siRNA, was carried out to see the effect of mirrored 
DAX-1 modification in the same cellular background yet with different endogenous 
DAX-1 expression levels. This system allows for subsequent analysis of downstream 
targets within specific pathways in Chapter 3. 
The treatment of E14 mESC with both siRNA and CRISPR-Cas9 allowed for two 
different methods with the same outcome – knock-down expression of endogenous 
Dax-1. Unlike the human mammary epithelial cell model, there is no variation in 
wild-type stem cells and Dax-1 is endogenously expressed in relatively high 
amounts. Each method uses different mechanisms for knocking down gene 
expression, and using both will allow any possible off-target effects of an individual 
method to be disregarded. The results of these treatments to mESC are used for 
subsequent analysis of candidate Dax-1 target genes in relation to pluripotency in 
Chapter 4. 
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Chapter 3 
DAX-1 Mediates Expression of Apoptosis-Inducing Genes in Human Breast 
Cancer  
Introduction 
Amongst the various human diseases, cancer poses a great threat to the human 
population.  As the life expectancy rises, so does the risk of cells functioning 
abnormally within the human body. The umbrella term of cancer mistakenly 
simplifies the complexity of the disease as a whole, which affects nearly every type 
of cell.  It is expected that there will be about 1.5 million new diagnosed cases in the 
United States in 2015. Estimates for 2015 in the United States alone put breast 
cancer as the second leading cause of cancer death for women, with about 40,000 
expected cancer deaths (Figure 3-1). Research of specific types of cancer is made 
possible with cell culturing of commercially available cell lines, such as MCF7 [41], 
that are well characterized and give great insight into the mechanisms and changes 
that contribute to onset and persistence of cancer.  
An early study linking DAX-1 to androgen receptor activity in human breast 
cancer cells saw a significant decline in cell proliferation with the introduction of 
exogenous DAX-1 into MCF7 [42]. Additionally, experiments in the Tzagarakis-
Foster lab brought to light the connection of DAX-1 to the decline of cell survival.  
Studies within our lab have confirmed that DAX-1 affects cell growth and survival 
from the aspect of proliferation through interaction with estrogen receptor, cyclin D, 
and Ki-67 [43]. Results from cell proliferation assays not only showed a decline in 
growth rate, but an overall decrease in cell population (Tzagarakis-Foster et al, 
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unpublished), indicating that cell death is another cause of the decline of survival as 
well. If DAX-1 was to be involved as a transcription factor with this cellular process, 
it is likely that it contributes to apoptosis, or programmed cell death.  
Results observed in MCF7 cells prompted further investigation in an opposing 
model system with DAX-1 highly and endogenously expressed. The lung 
adenocarcinoma cell line A549 was treated with siRNA to knock-down DAX-1 
expression, and the treated cells were compared with untreated cells in an 
apoptosis PCR array (Nguyen and Tzagarakis-Foster, unpublished).  Analysis and 
comparison of the gene expression of the genes (Figure 3-2) provided in the array 
allowed for the selection of candidate DAX-1 targets that work within known cell 
death pathways. Candidate genes that had demonstrated a fold-change, either 
decrease or increase, greater than two-fold were selected for further analysis. The 
number of genes that showed a change in expression with knock-down further 
confirmed a strong degree of DAX-1 influence on apoptosis. 
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Figure 3-1. Estimated Cancer Deaths in the US (Cancer Facts and Figures 2015, 
American Cancer Society). 
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Figure 3-2. Workflow of PCR Array (SABiosciences). Comparison of an untreated 
and treated sample is done by running individual plates and measuring relative 
expression of candidate genes, then calculating the fold change difference between 
samples. 
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Apoptosis is an efficient way for an organism to maintain tissue homeostasis and 
to clear old or aberrant cells. [44]. Evading apoptosis is one of the chief hallmarks of 
cancer [45]. Altering major apoptotic pathways gives cancerous cells an advantage 
over natural and artificial stressors that typically activate a cell death cascade. The 
cellular pathways that lead to cell death can be described as either extrinsic or 
intrinsic. Extrinsic programming is caused by extracellular death ligands 
interactions with transmembrane protein receptors.  Intrinsic programming is 
triggered by intracellular signals, such as elevated oncogene signaling and DNA 
damage, or upstream activity from extrinsic signaling pathways. While these 
pathways differ in their different specific molecular targets, they converge and lead 
to morphological changes within the cell as it begins to die. Cells going through early 
apoptosis can be identified through light microscopy by their characteristic 
shrinkage and visible chromatin condensation.  When going through the later stages 
of apoptosis, the plasma membrane separates from the cytoskeleton causing the cell 
to start blebbing, organelles get fragmented into apoptotic bodies, and the dead cell 
is then consumed by macrophages through phagocytosis [44].  
The breakdown of internal materials can be categorized into two pathways, 
distinguished by the use of caspases. The caspase-independent Granzyme A 
pathway is carried out through single-stranded DNA damage [46]. The more 
common pathway depends on caspases, the shortened name of cysteine-aspartic 
proteases, that are generally present as inactive proenzymes in a living, active cell 
[47]. Among the twelve known caspases, five are clearly involved with apoptosis. 
The five caspases are subcategorized by their mechanism of action: caspases 8 and 9 
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are initiators while caspases 3, 6, and 7 are executioners [48]. Once activated, these 
enzymes cleave proteins at aspartic acid residues, with each one specific depending 
on the neighboring amino acids [49] [50]. The inactivation and degradation of key 
proteins leads to the breakdown of internal components, and eventual breakdown 
of DNA through CAD, or caspase-activated DNase [51].  
The results from the knock-down of DAX-1 saw a change in expression of genes 
that fell within two major apoptotic, caspase-dependent pathways. The first 
category fell under the TNFα pathway, an extrinsic pathway that influences both cell 
proliferation and apoptosis. The TNFα ligand interacts with two receptors: TNFR-1, 
also known as p55, and TNFR-2, also known as p75. TNFR-1 mediates most 
apoptotic signaling [41], as seen in Figure 3-3, while TNFR-2 is upstream of anti-
apoptotic, cell proliferative, and cell survival signals such as NF-κB [52]. Upon 
interaction of the ligand with a death receptor like TNFR-1, the cytoplasmic “death 
domain” of the extracellular receptor recruits adapter proteins such as TRADD, 
FADD, and RIP. This recruitment associates with procaspase-8, resulting in the 
activation into caspase-8 and leading to downstream apoptotic effects [53].  
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Figure 3-3. TNFα pathway, with the major interactions leading to either cell 
proliferation or apoptosis through the triggering of the caspase cascade.  
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The second general category of genes that saw a change in expression in 
response to reduced DAX-1 was the BCL-2 family. This is a major intrinsic pathway, 
illustrated in Figure 3-4, that is strongly linked to programmed cell death, and is a 
major target for therapy due to its sole involvement with apoptosis alone [54]. 
There are three categories of proteins based on function and structure. Four distinct 
domains within the BCL-2 family, ranging from BH1 to 4, relate to their interactions 
with one another [55]. The first, most upstream members of the BCL-2 family are 
the BH3-only domain proteins. These proteins, such as BNIP3 and BID, are only able 
to interact with isoforms of BCL-2 [56]. By inhibiting anti-apoptotic members of 
BCL-2 and activating pro-apoptotic members, BH3-only proteins cause 
mitochondrial outer membrane permeabilization (MOMP), which releases internal 
proteins of the mitochondria and leads to the caspase cascade described earlier 
[57].  
 As mentioned earlier, while these two categories are distinct, they ultimately 
converge to result in the outcome of cell death. There is some crosstalk between the 
two different pathways when deciding on the activation of caspases. Ultimately, the 
genes were investigated by organizing them based on their function, rather than by 
protein family. The genes analyzed that inhibit apoptosis when expressed, or anti-
apoptotic genes, are listed in Table 3-1, while genes that function to promote 
apoptosis, or pro-apoptotic genes, are listed in Table 3-2. 
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Figure 3-4.  BCL-2 family apoptosis pathway. BH3-only proteins like BNIP3 
and BID are able to activate BAX and BAK proteins to cause membrane 
permeabilization of the mitochondria and release internal components like 
cytochrome c that cause activation of caspases.  
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Table 3-1. Anti-apoptotic candidate target genes. 
Gene Name Function 
TNFα Encodes a protein that is a death receptor ligand; when it binds to 
TNFR2, activates both cell proliferation and apoptotic pathways 
downstream [52] 
TRADD Encodes a death domain containing protein that suppresses 
TRAF2 recruitment of inhibitor-of-apoptosis proteins (IAPs) [58], 
but also has anti-apoptotic function because of influence on NFκB 
[59]   
TRAF1 Encodes a protein that associates with TRAF2 to form a complex 
needed to activate NFκB and activate IAPs  [58] 
BCL-XL Large isoform of BCL-2, encodes a transmembrane protein that is 
present in the mitochondria, prevents the release of cytochrome c 
[56] 
BCL-L2 Isoform of BCL-2 that prevents the release of cytochrome c [56] 
BCL2-A1 Isoform of BCL-2 that prevents the release of cytochrome c [56] 
BCL-L10 Isoform of BCL-2 that prevents release of cytochrome c [56] 
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Table 3-2. Pro-apoptotic candidate target genes. 
Gene Name Function 
BCL-XS The shorter isoform of BCL-2 that acts as an apoptotic activator 
by allowing for the release of cytochrome c [56] 
BCL2-L1 One of the smaller isoforms of BCL-2 that allows for the release of 
cytochrome c [56] 
BAX A BH1 through 3 domain containing protein that associated with 
the membrane to release cytochrome c [56] 
BAD A BH3-only protein that forms a heterodimer with anti-apoptotic 
proteins to prevent the inhibition of apoptosis [56] 
TRAF3 Activates the immune response and contributes to the 
lymphotoxin-beta receptor signaling complex, which induces 
NFκB activation and cell death [58] 
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Methodology  
While the changes in the gene expression in the mentioned pathways were 
significant enough to suggest some influence, some sort of measurement of the 
actual occurrence of apoptosis with DAX-1 presence is required to confidently 
associate DAX-1 with apoptosis. Annexin V and propidium iodide staining can be 
used to quantify cells undergoing apoptosis through cell flow cytometry. During 
early apoptosis, the membrane protein phosphatidylserine is flipped to the exterior 
of the cell, which allows for Annexin V to bind and tag a cell.  As a cell progresses 
through the breakdown of internal components, DNA is more readily accessible and 
stained by propidium iodide (Figure 3-5A). Cell flow cytometry allows for the 
comparison of the degree of staining with these two reagents to identify and 
characterize cells within a population sample (Figure 3-5B). 
If a candidate gene displays a mirrored change in expression with changes in 
the amount of DAX-1 presence, chromatin immunoprecipitation (ChIP) is an assay 
that can be used to test for the presence of DAX-1 within the regulatory region of the 
target gene. One form of this technique, called X-ChIP, crosslinks proteins attached 
to DNA. With the proteins locked onto the genome, cells are lysed and the chromatin 
is sheared through sonication into smaller fragments for easier analysis. The target 
protein, still attached to DNA, is selected using antibodies or any other method 
specific to the protein. The DNA and proteins are then separated, and the fragments 
of DNA are used for further analysis (Figure 3-6). 
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A.  
 
B.  
 
Figure 3-5. Annexin V and PI staining of apoptotic cells. A.  The attachment of 
the dyes Annexin V-FITC and propodium iodide (PI) depend on the accessibility of 
the membrane protein phosphatidylserine (PS) and chromatin, respectively. Cells 
that are going through early apoptosis will have PS flipped outwardly, and cells 
going through late apoptosis or necrotic cells will also have chromatin readily 
stained with PI due to breakdown of the nucleus. B. Quantification of cells based on 
the amount of staining of both reagents is carried out by cell flow cytometry and 
graphed on the computer. 
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Figure 3-6. Workflow of X-ChIP Assay (AbCam). Untreated or treated cells are 
treated with formaldehyde in order to leave proteins in contact with genomic DNA 
to stay attached. Cells are then lysed and the chromatin is sheared to 300 to 500 
base pair fragments. Antibodies are added, and samples are immunoprecipitated to 
isolate the fragments with protein(s) of interest. Proteins are released and the 
remaining DNA fragments are purified for downstream analysis.  
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Materials and Methods 
RNA and cDNA extraction 
MCF7 human breast cancer cells and MCF10A human normal breast cells, 
untreated and treated as stated in Chapter 2, were lysed and messenger RNA 
was collected using QIAGEN RNeasy Kit according to the manufacturer’s 
protocol.  Nucleic acid concentrations were measured using the GE Nanovue 
Plus Spectrophotometer.  Complementary DNA (cDNA) was then synthesized 
from 1 μg of collected mRNA using various kits (High Capacity cDNA Reverse 
Transcription Kit from Applied Biosystems; M-MuLV Reverse Transcriptase 
from New England Biolabs; QuantiTect Reverse Transcription Kit from 
QIAGEN) according to the corresponding protocol. 
 
Small Molecule Inhibitor 
BADGE (Bisphenol A diglycidyl ether; 2,2'-[(1-Methylethylidene)bis(4,1-
phenyleneoxymethylene)]bis-oxirane), a TNFα inhibitor that is known to 
induce apoptosis in tumor cells, was prepared to a working concentration of 
1 mM in 100% ethanol from the stock (Santa Cruz Biotech, cat no. sc-
202487). 100 μL was used in each well of a twelve-well plate. Cells were 
treated for 48 hours before collection and flow cytometry analysis.  
 
Flow Cytometry 
MCF7 cells were plated in twelve-well dishes and either untreated, 
transfected with pcDNA-DAX-1 as stated in Chapter 2, treated with BADGE 
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alone, or BADGE and pcDNA-DAX-1. After collection, each treatment of cells 
was left unstained, stained with Annexin V alone, stained with PI alone, or 
stained with the combination of Annexin V and PI. Cells were quantified 
using the BD Accuri C6 Cytometer and its provided computer program, with 
a sample size of 10,000 cells per reading. 
 
Polymerase Chain Reaction (PCR) 
Annealing temperatures were optimized using Promega GoTaq Green Master 
Mix. Primers listed in Table 3-5 and any subsequent primers used were all 
ordered from Integrated DNA Technologies. Conditions in Table 3-3 were 
used, with optimized annealing temperatures for specific primer pairs used 
for step 3. Upon completion, samples were removed from the 4°C hold and 
stored until further analysis. 
 
Table 3-3. Thermocycler conditions and steps for standard PCR. 
Step Temperature Time 
1 95°C 5 minutes 
2 95°C 30 seconds 
3 53-60°C 30 seconds 
4 72°C 30 seconds 
5 Repeat steps 2 to 4 x thirty times 
6 4°C ∞ 
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Real-Time PCR (qPCR) 
Quantitative PCR analysis was performed on untreated and treated cDNA 
collected from MCF7 and MCF10A cells to analyze the relative gene 
expressions of target genes, normalized with GAPDH expression. SYBR green 
master mixes (BioRad and QIAGEN) and the respective primer pairs for the 
genes listed in Table 3-5 were used for apoptotic gene analysis. Primers with 
a source as “construct” were designed using NCBI Primer-BLAST using the 
available cDNA sequences online. Each sample was prepared using 10 μL of 
SYBR green master mix, 0.25 μL of the forward primer, 0.25 μL of the reverse 
primer, 7.5 μL nuclease free water, and 2 μL of cDNA. All samples were run in 
triplicate for 40 cycles using the two-step amplification program, outlined in 
Table 3-4, with the BioRad CFX96 Touch Real-Time PCR Detection System. 
Results were analyzed using the BioRad CFX Manager™ software and 
Microsoft Excel. 
 
Table 3-4. Thermocycler conditions and steps in the two-step amplification 
program for qPCR. Fluorescent dye detection occurred at step 3. 
Step Temperature Time 
1 95°C 5 minutes 
2 95°C 30 seconds 
3 55-60°C 15 seconds 
4 Repeat steps 2 and 3 x thirty-nine times 
 
 64 
Statistical Anaylsis 
Data from the qPCR analysis are presented with the mean + standard 
deviation of triplicate experiments. Statistical significance is calculated in the 
same manner described in Chapter 2.  
 
Table 3-5. Primers used for apoptosis qPCR analysis. 
Gene FWD REV Source 
TNFα GGAGAAGGGTGACCGACTCA CTGCCCAGACTCGGCAA Construct 
TRAF2 TGGCTGGCCGCATACC TGTAGCCGTACCTGCTGGTG
TA 
Construct 
TNFR1 TACATTGCAGCCTCTGCCTC AGAGCTTGGACTTCCACCGT Construct 
TNFR2 ACATCAGACGTGGTGGTGCA
A 
CCAACTGGAAGAGCCAAGTC [59] 
TRADD AGCTCATAGTGAACCGGCCA TCCCTCAGTGCTCGACAGC Construct 
BCL-XS CTGCACCTGACGCCCTTCAC
C 
CACATGACCCCACCGAACTC
AAAGA 
Construct 
BCL-XL GATCCCCATGGCAGCAGTAA
AGCAAG 
CCCCATCCCGGAAGAGTTCA
TTCACT 
Construct 
BAX ATGGAGCTGCAGAGGATGAT
T 
TGAAGTTGCCATCAGCAAAC
A 
Construct 
BCL2-L10 GCCTTCATTTATCTCTGGAC
ACG 
GAAGGTGCTTTCCCTCAGTT
CTT 
Construct 
BCL2A1 CCCGGATGTGGATACCTATA
AGGAGA 
GTCATCCAGCCAGATTTAGG
TTCA 
Construct 
ERα GACAGGGAGCTGGTTCACAT  AGGATCTCTAGCCAGGCACA Construct 
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Western Blot 
Protein lysates were collected from untreated and treated cells grown in six 
well plates according to protocol using M-PER Mammalian Protein Extraction 
Reagent (Thermo Scientific).  Protein concentrations of collected cell lysates 
were determined by Bradford Protein Assay using a bovine serum albumin 
(BSA) dilution standard.  Lysates normalized to 10,000 ng total per well were 
prepared for SDS-PAGE gel electrophoresis using Novex NuPage LDS and 
Reducing Agent (Thermo Scientific).  Samples were electrophoresed through 
a NuPage 4-12% Bis-Tris precast gel at 200 V for 45 minutes in 1X MOPS 
running buffer and then transferred onto a PVDF membrane in NuPage 
Transfer buffer with 20% methanol.  The PVDF membrane(s) were blocked 
in 5-10% Blotto in TBST prior to incubation with appropriate antibodies 
(Santa Cruz Biotechnology, Inc. and ActiveMotif) as listed on Table 3-6 in a 
1:1000 dilution in Blotto. Blots were then treated with secondary mouse or 
rabbit antibodies based on the host of the primary antibodies diluted 1:2000 
in 5% Blotto in TBST. Protein bands were developed using the Clarity ECL 
Western Blotting substrate kit (BioRad) according to protocol and visualized 
using a BioRad Gel Doc™ XR+ System with the ImageLab software. 
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Table 3-6. Monoclonal Antibodies used for Western Blotting. 
Protein Target Host Organism Cat. No, Company 
Beta-Actin Mouse sc-82278, Santa Cruz 
GAPDH Rabbit 3683, Cell Signaling 
DAX-1 Mouse 39983, ActiveMotif 
BCL-2 (XL isoform) Rabbit GTX127958, GeneTex 
BAX Rabbit GTX109683, GeneTex 
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Chromatin Immunoprecipitation (ChIP) 
MCF7+DAX1 cells were collected for treatment using the AbCam 500 ChIP kit 
according to protocol. Antibodies for the protein targets listed in Table 3-7 
were used. Primers used to analyze the promoter regions of two possible 
targets, broken down into individual regions (Figure 3-7) were designed 
using NCBI’s Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) and are shown in Table 3-8.  
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A.   
 
 
B.  
 
 
Figure 3-7. Targeted regions of the A. BCL-2 and B. BAX promoter. Each region 
has an individual length of about 200 to 300 base pairs. 
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Table 3-7. Antibodies used for ChIP assay. 
Protein Target Host Organism Cat. No, Company 
Histone H3 Rabbit (polyclonal) 1791, AbCam 
DAX-1 Mouse (monoclonal) 39983, ActiveMotif 
ERα Rabbit (polyclonal) GTX100634, GeneTex 
 
 
Table 3-8. Primer sets corresponding to promoter regions of BCL-2 and BAX. 
 
Gene Region FWD REV 
BCL-2 Region 3 CCCCTCGTCCAAGAATGCAA CATCTCCCGCATCCCACTC 
Region 4 ACGCCCCATCCAGCCG CCCGCGCGGTGAAGG 
BAX Region 1 GGGTGGCTCAAGCCTGTAATC GAGTGCAGTGGCCCAATCAT 
Region 2 GAGCCATGATTGGGCCACTG CCAGGCAGGACGTTATAGAT 
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Results 
Introduction of DAX-1 increases number of apoptotic cells in population 
 Cell flow cytometry was used to quantify the number of early and late 
apoptotic cells. The number of cells that fell in the right hand quadrants in Figure 3-
4A were quantified in Figure3-4B.  There was a significant increase of apoptotic cells 
in the MCF7-DAX-1 samples, specifically from 1.3% to 23.2%.  Cells treated with 
BADGE alone saw a similar significant increase from 1.3% to 29.7%. There was no 
significant difference between singular treatment of BADGE or pcDNA-DAX-1 alone 
compared to BADGE and pcDNA-DAX-1 (31.3%) in combination. 
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A.  
 
B. 
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Figure 3-8. Cell flow cytometry of Annevin V and propidium iodide stained 
MCF7 cells untreated and treated with pcDNA-DAX1. A. Contour diagram of 
FITC-Annexin V/PI flowcytometry of MCF7 calls after 48 hour collection following 
transfection with pcDNA-DAX-1, and either no treatment or treatment with BADGE, 
or untransfected (UT) cells. B. Quantification of the right-hand quadrants from each 
cell flow cytometry sample to give value to the number of apoptotic cells with or 
without treatment. Error bars shown represent 5% error of shown value.  
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Changes in candidate genes within MCF10A DAX-1 knock-down cells 
MCF10A cells that underwent siRNA treatment in order to transiently knock-
down DAX-1 expression, treated as stated in Chapter 2, were lysed for collection of 
mRNA. Complementary DNA synthesized from the collected mRNA of treated and 
untreated cells were then analyzed by qPCR to compare gene expression changes. 
Among the anti-apoptotic candidate genes that were analyzed (Figure 3-9), BCL-L2 
(A), BCL-XL (B), TNFα (D), and TRADD (G) increased in expression, while BCL2-A1 
(C), TRAF1 (E), and BCL-L10 (F) decreased in expression. For the pro-apoptotic 
genes that were analyzed (Figure 3-10 A-E), BAX, BAD, BCL-XS, BCL-L1, and TRAF3 
all showed varied degrees of significant decreased expression. 
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A.       B.  
 
 
C.       D.  
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E.       F. 
 
G.  
 
Figure 3-9. qPCR results of anti-apoptotic candidate genes tested in MCF10A 
knock-down total mRNA samples. Relative expression values were normalized 
using the expression of GAPDH to compare treated siRNA knock-down samples to 
untreated samples. Results shown correspond to candidate genes A. BCL-L2, B. BCL-
XL, C. BCL2-A1, D. TNFα, E. TRAF1, F. BCL-L10, and G. TRADD. A single asterisk (*) 
represents samples that were p<0.05, a double asterisk (**) represents samples that 
were p<0.005, and a triple asterisk (***) represents samples that were p<0.001. 
Error bars on qPCR results represent standard deviation of the mean.  
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A.       B.  
 
 
C.       D.  
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E.       
 
Figure 3-10. qPCR results of pro-apoptotic candidate genes tested in MCF10A 
knock-down total mRNA samples. Results shown correspond to the candidate 
genes A. BAX, B. BAD, C. BCL-XS, D. BCL-L1, and E. TRAF3. A single asterisk (*) 
represents samples that were p<0.05, a double asterisk (**) represents samples that 
were p<0.005, and a triple asterisk (***) represents samples that were p<0.001.  
Error bars on qPCR results represent standard deviation of the mean. 
 
  
 78 
Changes in candidate genes within MCF7 pcDNA-DAX-1 cells 
 The cDNA synthesized from collected mRNA of MCF7 cells, treated as 
described in Chapter 2 to express DAX-1, was analyzed by qPCR to compare gene 
expression changes of specific candidate genes. The gene expression of anti-
apoptotic gene candidates BCL-XL, TRAF1, and TRADD (Figure 3-11 A, C, D) showed 
a significant decrease in expression with DAX-1 treatment , while BCL-L2 (Figure 3-
11B) saw slight decrease but was not statistically significant. Of the pro-apoptotic 
genes analyzed (Figure 3-12), BAX (A) saw a significant increase in expression, 
while BCL-XS (C) and TNFR1 (F) saw a significant decrease. The genes BAD (B), 
BCL2-L1 (D), and TRAF3 (E) also saw a decrease in expression, but were not 
statistically significant.  
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A.      B.  
   
C.       D.  
      
Figure 3-11. qPCR results of anti-apoptotic candidate genes tested in MCF7 
knock-down total mRNA samples. Results shown correspond to the A. BCL-XL, B. 
BCL-L2, C. TRAF1, and D. TRADD genes. A single asterisk (*) represents samples that 
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a 
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR 
results represent standard deviation of the mean. 
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A.       B.  
 
 
C.       D.  
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E.       F.  
 
Figure 3-12. qPCR results of pro-apoptotic candidate genes tested in MCF7 
knock-down total mRNA samples for candidate genes A. BAX, B. BAD, C. BCL-XS, 
D. BCL2-L1, E. TRAF3, and F. TNFR1. A single asterisk (*) represents samples that 
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a 
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR 
results represent standard deviation of the mean. 
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Selected genes further analyzed for expression changes reflected in protein expression 
 The genes BAX (Figure 3-10A and Figure 3-12A), the large BCL-2 isoform 
BCL-XL (Figure 3-9B and Figure 3-11A), and TRADD (Figure 3-9G and Figure 3-11D) 
were observed to have significant mirrored expression with the opposing DAX-1 
expression models, as listed in Table 3-9. BAX, a pro-apoptotic protein, and BCL-XL, 
an anti-apoptotic isoform of the BCL-2 protein, were selected for further analysis of 
DAX-1 transcriptional regulation. The changes in gene expression were reflected in 
the amount of protein produced based on DAX-1 level changes, as seen in Figure 3-
13. BAX saw an increase when DAX-1 was present and a decrease when DAX-1 
expression was reduced, while BCL-XL saw a decrease with DAX-1 introduction and 
increase with DAX-1 knock-down. 
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Table 3-9. Comparison of candidate genes in MCF10A and MCF7 cells.  Relative 
increase in expression is indicated by an up arrow (), a decrease is indicated by a 
down arrow (), and degree of significance is noted in parentheses. Significance is 
either noted with a number of asterisks or labeled (n.s.) for not significant. A single 
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents 
samples that were p<0.005, and a triple asterisk (***) represents samples that were 
p<0.001.  Not all treated samples were tested for each candidate genes. 
Type Gene 
MCF10A 
(siDAX-1) 
MCF7 
(pcDNA-DAX-1) 
Anti-apoptotic 
BCL-L2  (*)  (n.s.) 
BCL-XL  (**)  (***) 
BCL2-A1  (***)  
TNFα  (*)  
TRAF1  (**)  (***) 
BCL-L10  (***)  
TRADD  (*)  (**) 
Pro-apoptotic 
BAX  (*)  (**) 
BAD  (**)  (n.s.) 
BCL-XS  (***)  (**) 
BCL-L1  (***)  (n.s.) 
TRAF3  (***)  (n.s.) 
TNFR1   (*) 
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Figure 3-13. Western blot of candidate DAX-1 targets BCL-XL and BAX. BCL-XL, 
the anti-apoptotic isoform of BCL-2, saw a decrease of protein expression with the 
introduction of DAX-1, and an increase with the knock-down of DAX-1 expression. 
BAX, a pro-apoptotic protein in the BCL-2 family, was observed to have an increase 
in expression with the introduction of DAX-1, and a decrease in expression with the 
knock-down of DAX-1 expression. GAPDH was used as a control. 
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ChIP analysis of BCL-2 and BAX promoter regions 
The promoter regions of BCL-2 and BAX were broken up into five regions, 
with each region having a length of about 200-300 base pairs (Figure 3-7).  Among 
the regions tested, the presence of DAX-1 was detected in region 4 for BCL-2, that 
corresponds to a section that spans a range of 442 to 225 base pairs upstream of the 
BCL-2 transcription start site. This is shown in both a detectable band in agarose gel 
electrophoresis of PCR samples using primers for region 4 (Figure 3-14A) and a 
significant qPCR value when compared to both negative and positive controls 
(Figure 3-14B). Results from region 3 were used in comparison as a section with no 
detectable DAX-1 binding. Additionally, ERα is known to bind to the BCL2 promoter 
based on a response to estradiol [60], and was similarly detected with significant 
qPCR values. 
DAX-1 was also detected in Region 2 of the BAX promoter region (results not 
shown), which corresponds to a distance of 761 to 484 base pairs upstream of the 
transcription start site.  
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A.     
 
B.  
 
 
Figure 3-14. Chromatin immunoprecipitation (ChIP) experiments targeting 
DAX-1 binding to the BCL-2 promoter. A. Agarose gel electrophoresis of PCR 
products using primers targeting region 4 of the BCL-2 promoter and B. qPCR 
results comparing the transcript amounts from ChIP experiments using IgG (as a 
negative control), Histone H3 (as a positive control), DAX-1, and ERα antibodies. A 
single asterisk (*) represents samples that were p<0.05, a double asterisk (**) 
represents samples that were p<0.005, and a triple asterisk (***) represents 
samples that were p<0.001. Error bars on qPCR results represent standard 
deviation of the mean. 
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Discussion 
 After verifying the success of DAX-1 expression modification in Chapter 2, 
the influence of DAX-1 on apoptosis was tested through cell flow cytometry of cells 
stained with Annexin V and PI (Figure 3-8). The increase in the number of apoptotic 
cells in the entire population was comparable to a known apoptotic inducer BADGE, 
confirming the association of DAX-1 with programmed cell death overall. There was 
no additive effect of the combination of DAX-1 knock-in with BADGE treatment. The 
treatment with both DAX-1 and BADGE appears to affect the same pathway, rather 
than through different and alternate pathways. The BADGE reagent affects 
apoptosis through TNFα very far upstream, therefore the DAX-1 target(s) would 
likely lie downstream of the affected members of the pathway. 
 The MCF7 and MCF10A cells, treated as described in Chapter 2, served as the 
opposing DAX-1 expression models. Genes that clearly showed mirrored expression 
changes with the opposing models would be selected for further analysis, as these 
changes strongly suggest a direct interaction as caused by varied DAX-1 expression, 
rather than by the changes in the balance of apoptotic pathways. Among the 
analyzed candidate genes, three showed significant mirrored changes: the large 
BCL-2 isoform BCL-XL (Figure 3-9B and Figure 3-11A), TRADD (Figure 3-9G and 
Figure 3-11D), and BAX (Figure 3-10A and Figure 3-12A). TRADD was ruled out for 
further analysis because some of its regulation occurs post-transcriptionally, like by 
gonadotropin-regulated testicular helicase (GRTH) interacting with TRADD mRNA 
[61]. Meanwhile, research into BCL-2 and its family members has focused to a large 
degree on transcriptional regulation due to key recognition elements [62], with 
 88 
some more recent research into post-transcriptional regulation [63]. For these 
reasons, BCL-2 (interchangeably referred to as BCL-XL because of the large, anti-
apoptotic isoform) and BAX were selected for further analysis. The changes in gene 
expression were reflected in the changes of the protein level (Figure 3-13). This not 
only confirms that DAX-1 affects the protein level at the gene level, but also 
reaffirms the idea that with DAX-1 apoptosis is promoted, while removing DAX-1 
shifts away from an apoptotic profile. 
 The ChIP assays showed the presence of DAX-1 far upstream from the BAX 
gene transcription start site, and relatively closer to the BCL-2 transcription start 
site (Figure 3-14A). DAX-1 is unable to bind to the promoter directly on its own, 
therefore it is likely DAX-1 binds to another transcription factor already occupying 
the promoter, much like a “piggyback” fashion.  Available ChIP assays also showed 
that ERα is detected in the same region on the BCL-2 promoter, and this was 
confirmed with our own experiments (Figure 3-14B). Given the strong relation of 
DAX-1 and ER in breast cancer [64], the suggestion of an interaction between these 
two proteins is highly likely.  This can be further confirmed if DAX-1 would have less 
of an effect on apoptosis in an ER negative breast cancer line.  Additionally, this 
means of interacting with apoptosis through ER interaction may also be reflected in 
other key biological processes important to cancer cells. These results reveal a 
fraction of an answer to the overall question of DAX-1’s positive contributions to 
breast cancer, but strongly suggest that DAX-1 regulates the expression BCL-2 with 
a transcription factor partner that, in turn, affects the apoptotic aspect of cell 
survival. 
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Chapter 4 
Dax-1 Knock-down Effects on Pluripotent Gene Network in Mouse Embryonic 
Stem Cells 
Introduction 
Stem cells are characterized by two defining properties: self-renewal and 
pluripotency [65].  Self-renewal is the continued replication of a cell lineage, 
allowing for preservation of population of cells, while pluripotency is the capacity of 
a cell to differentiate into a variety of cell types, more notably into all three germ 
layers: the ectoderm, mesoderm, or endoderm [66].  There are distinct pluripotent 
stem cell types, distinguished by when the cells are harvested from an embryo. As 
illustrated in figure 4-1, embryonic stem cells (ESCs) are harvested from the inner 
cell mass (ICM) of a blastocyst after embryo day 5, while the outer cells can be 
cultured into trophoblast stem cell (TSC) lines. As the blastocyst matures and the 
ICM begins to divide into distinct layers by the fifth and sixth embryonic day, 
embryonal carcinoma cells (ECCs) can be harvested from the embryo [67].  
Embryonic stem cells are the most commonly used cells in mouse and human 
stem cell research. In vitro culturing of mouse ESC was successfully developed to 
maintain pluripotency of cells in tissue culture with the presence of leukemia 
induction factor (LIF) [68]. The embryonic stem cells typically require the presence 
of feeder cells that served as the source of LIF, but continued harvesting of mouse 
ESC has allowed for specific lines that can be maintained without feeder cells [69], 
which are adherent growth-arrested cells that are incapacitated and have the sole 
purpose of releasing key nutrients required for the maintenance of the stem cell 
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state [70]. These cell lines can be implanted in a developing embryo and still 
differentiate into all three types of germ cells, allowing for genetic modification of 
entire organisms.   
Established ES cell lines are maintained by complex protein networks [71, 
72], with distinct key transcription factors such as Oct3/4 [73], Sox2 [74], and 
Nanog [75] that strongly drive the maintenance of pluripotency, and additional 
factors such as Stat3 [76] and c-Myc [77] that contribute to self-renewal. These 
connections were made through various knock-down studies, both of individual and 
a combination of candidate factors [78, 79]. Through these studies, no one single 
gene was the sole factor for maintaining the pluripotent state. Likewise, since the 
maintenance of a pluripotent state has a number of factors centered in the complex 
interactions, it was found that reversing differentiated adult mouse fibroblasts 
needed a combination of some of these key factors (OCT3/4, Sox2, c-Myc, and Klf4) 
to return stem cell-like state [80]. Untangling the network of transcription factors 
that keeps pluripotency in check therefore opens up a range of therapeutic 
possibilities in the medical world. 
 When Dax-1 was knocked down in mouse stem cells, it was found that the 
loss of Dax-1 alone was not sufficient to change the phenotype of the population of 
cells, just like the other key factors. However, there were interactions with many key 
pluripotency genes that brought Dax-1 into the spotlight as an important 
contributor to the pluripotent state [81]. 
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Figure 4-1. Stem cell origins in the mammalian embryo. Pre-ICM (inner cell 
mass cells) transition to ICM cells during blastulation at embryonic day 3-4. After 
this occurrence, ES cells can be harvested from the organism and established in 
vitro.  
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Target Genes 
Research carried out previously in the Tzagarakis-Foster lab identified a 
number of notable genes that Dax-1 appears to interact with, based on changes in 
gene expression between wild-type mESCs and Dax-1 knocked-down mESCs [82]. 
Candidate genes were selected based on observations of a significant fold change in 
expression through tests in a pluripotency PCR array. The known roles and 
contributions to overall cell activity of a subset of the selected genes are elaborated, 
and give hints to the mechanisms by which Dax-1 is contributing to pluripotency, as 
shown in Table 4-1. Furthermore, additional genes of interest were added to the 
pool of genes examined based on known interactions with Dax-1 in contexts outside 
of stem cells. 
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Table 4-1. Dax-1 candidate target genes in mESC and their role in mediating 
pluripotency and differentiation. 
Target Gene Description 
Nanog  
Key player in maintenance of pluripotency and self-renewal 
[83] 
Pou5f1; 
OCT3/4 
Key player in maintenance of pluripotency and self-renewal 
[73, 84] 
GATA6 Drives differentiation and organogenesis [85] 
SOX2 
Known to interact with Oct3/4; together with SOX3, encodes the 
protein SOXB1. Key play Key player in maintenance of pluripotency 
and self-renewal [86] 
SOX9 
Known to interact with DAX1 in male sexual development through 
the expression of SRY from the Y chromosome [87] 
SOX17 Drives differentiation and cell fate determination [86] 
T 
Brachyury is part of the family of T-box transcription factors; 
contributes to the formation and organization of the mesoderm 
layer during embryogenesis; also refered to as T-Brachyury [88] 
Lefty2 
Part of the TGFbeta family, which as a whole is involved in cell 
growth, cell differentiation, apoptosis, homeostasis; required for the 
left-right asymmetry determination of organogenesis [89] 
AMH 
Anti-Mullerian hormone, also known as MIS (Mullerian inhibiting 
substance), is part of the TGFbeta family as well. It is known 
primarily for its role in male sexual development through inhibition 
of Mullerian ducts, allowing for proper development of Wolffian 
ducts. [90] 
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Materials and Methods 
RNA and cDNA extraction 
mESC were treated using siRNA and CRISPR experiments as described in 
Chapter 2. The mRNA of these cells were extracted and isolated as described 
in Chapter 3. 
 
Target Genes 
Based on the information produced by previous studies [82] and additional 
genes of interest, the following table lists the forward and reverse primers 
used for the isolation of gene fragments and measurement of overall gene 
expression by quantitative PCR. 
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Table 4-2. Pluripotency candidate gene primers. 
Gene FWD REV Source 
Dax-1 TCCTGTACCGCAG
CTATGTG 
TGCAAGTGCAGGTGA
TCTTG 
[82, 91]  
GAPDH (1) ACAGCCGCATCTT
CTTGTGCA 
GGCCTTGACTGTGCCG
TTGAA 
[82] 
GAPDH (2) CCATCACCATCTT
CCAGGAGCG 
AGAGATGATGACCCT
TTTGGC 
Construct 
Nanog TTCTTGCTTACAA
GGGTCTGC 
AGAGGAAGGGCGAGG
AGA 
[91] 
GATA6 ATGCTGTCCGGCC
TGCCCTA 
GTTCACGCACTCGCGG
CTCT 
[82] 
T-Brachyury CTGCGCTTCAAGG
AGCTAAC 
CCAGGCCTGACACATT
TACC 
[81] 
Oct3/4 CTCCCGAGGAGTC
CCAGGACAT 
GATGGTGGTCTGGCTG
AACACCT 
[81] 
SOX2 ACAAGAGAATTGG
GAGGGGT 
AAAGCGTTAATTTGG
ATGGG 
mouseprimerdepot 
SOX9 AGGAAGCTGGCAG
ACCAGTA 
TCCACGAAGGGTCTCT
TCTC 
mouseprimerdepot 
SOX17 TGGAACCTCCAGT
AAGCCAG 
TCAGATGTCTGGAGG
TGCTG 
mouseprimerdepot 
AMH GGGAGACTGGAGA
ACAGCAG 
GGTGGAGGCTCTTGG
AACTT 
mouseprimerdepot 
Lefty2 CATGAAGTCCCTG
TGGCTTT 
TGCAGTAGACTGCTCA
GGACC 
mouseprimerdepot 
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Polymerase Chain Reaction (PCR) 
Annealing temperatures were optimized using GoTaq Green Master Mix 
(Promega), Taq 2X Master Mix (New England Biolabs), and FailSafe PCR 
System (Epicentre) kits. Reactions were run with the same protocol listed in 
Table 3-3.  
 
Real-Time PCR (qPCR) and Statistical Analysis 
Reagents and equipment used for RT-PCR experiments and statistical 
analyses were carried out as described in Chapter 2.  
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Results 
Gene expression changes with siRNA Dax-1 knock-down 
 After treating the mouse embryonic stem cells with siRNA transcripts in 
order to modify high Dax-1 expression, as described in Chapter 2, collected cDNA 
was used for qPCR analysis of candidate target pluripotency genes (Figure 4-2). 
Among the genes tested, Nanog and lefty2 saw a significant increase in relative 
expression after siDax-1 treatment. Expression of the genes SOX2, SOX17, GATA6, 
and T-Brachyury saw a significant decrease (Figure 4-2 B, C, F, and G), while OCT3/4 
and SOX9 (Figure 4-2 H and I) saw a non-significant decrease in expression. The 
expression of AMH (Figure 4-2D) did not change. These changes are also 
summarized in part of Table 4-4.  
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I.  
 
Figure 4-2. qPCR results of siRNA Dax-1 knock-down mESC. Graphs correspond 
to the candidate genes: A. Nanog, B. SOX2, C. SOX17, D. AMH, E. Lefty2, F. GATA6, G. 
T-Brachyury, H. OCT3/4, and I. SOX9. A single asterisk (*) represents samples that 
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a 
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR 
results represent standard deviation of the mean. 
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Gene expression changes with CRISPR-Cas9 treatment 
 Following the CRISPR-Cas9 treatment described in Chapter 2, stable cells 
that were treated with CRISPR guide 3 that targeted an early section of exon 1 and 
showed Dax-1 knockout were harvested and used for analysis of the candidate 
genes (Figure 4-3). Nanog (A), Lefty2 (E), and T-Brachyury (G) saw a significant 
increase in expression with the disruption of Dax-1 expression. SOX2 (B), SOX17 (C), 
GATA6 (F), OCT3/4 (H), and SOX9 (I) saw significant decreases in expression. 
Lastly, AMH (D) showed no change in expression when comparing untreated to 
treated samples. These results are also summarized in Table 4-3. 
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I.  
 
Figure 4-3. qPCR results of CRISPR Dax-1 knock-down mESC. The cells used 
were treated with guide 3, targeting exon 1 of Nr0b1. Graphs correspond to the 
candidate genes: A. Nanog, B. SOX2, C. SOX17, D. AMH, E. Lefty2, F. GATA6, G. T-
Brachyury, H. OCT3/4, and I. SOX9. A single asterisk (*) represents samples that 
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a 
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR 
results represent standard deviation of the mean. 
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Table 4-3. Comparison of siRNA and CRISPR Dax-1 candidate gene results. 
Relative increase in expression is indicated by an up arrow (), a decrease is 
indicated by a down arrow (), no change indicated by an x-symbol (), and degree 
of significance is noted in parentheses. Significance is either noted with a number of 
asterisks or labeled (n.s.) for not significant. A single asterisk (*) represents samples 
that were p<0.05, a double asterisk (**) represents samples that were p<0.005, and 
a triple asterisk (***) represents samples that were p<0.001. 
Gene siRNA CRISPR-Cas9 
Nanog  (**)  (***) 
SOX2  (***)  (***) 
SOX17  (***)  (***) 
AMH  (n.s.)  (n.s.) 
Lefty2  (***)  (***) 
GATA6  (***)  (***) 
T-Brachyury  (***)  (***) 
OCT3/4  (n.s.)  (*) 
SOX9  (n.s.)  (*) 
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Discussion 
 Using the mESC samples that were treated as outlined in Chapter 2, selected 
candidate genes were examined for changes in gene expression. In order to further 
validate the expression changes, two different methods were used to knock-down 
Dax-1 expression. The comparison using the cDNA of both methods to observed 
gene expression changes are shown in Table 4-3. 
 Overall, both methods were successfully able to knock-down Dax-1 
expression, both transiently through siRNA and permanently through CRISPR-Cas9. 
It is very clear that Dax-1 is not a master regulator, since expression of key markers 
such as Nanog surprisingly increased, while others such as OCT3/4 experienced 
only a slight decrease in expression. However, changes in particular genes involved 
with specific cell fates suggest that Dax-1 is not a key regulator because it appears to 
only be involved with certain pathways towards differentiation. For example, the 
knockdown of Dax-1 appears to have strong effect on the expression of Lefty2, a 
gene involved in proper asymmetric development of cells that differentiate to be 
part of the mesoderm [89]. Another gene that was especially affected with the long-
term removal of Dax-1 was T-Brachyury, which is required for mesoderm formation 
[92].  
The increase in expression in these genes involved with mesoderm 
formation, despite the maintenance of key genes, may be enough to tip the scales 
towards differentiation within a population of cells. To confirm if Dax-1 has the 
strongest interaction with mesoderm genes, the candidate list can be expanded to 
include genes involved with this specific fate should be investigated in the future. 
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 To further confirm if the interactions with genes of interest are direct or not, 
additional ChIP experiments can be carried out as described in Chapter 3. However, 
it should be noted that there are research groups who have already carried out 
large-scale ChIP assays with publically accessible results. This allows for a 
computer-based approach to sorting through data to confirm Dax-1 interactions 
based on detection in regulatory regions of genes. 
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Chapter 5 
Functional enrichment analysis of Dax-1 ChIP-seq high-throughput data 
Introduction 
As described in Chapter 3, chromatin immunoprecipitation assays are often 
employed to investigate whether a protein of interest is present in complex to 
specific promoter regions of select target genes. The samples resulting from X-ChIP 
are typically used for analysis of a small number of regulatory regions, often with 
primers flanking a region designated by the user. On a slightly larger scale, ChIP-
chip allows one to analyze the resulting DNA fragments on a chip array with a pre-
selected set of primers for known regulatory regions. When scaled up even more 
and paired with massive parallel sequencing, conventional ChIP becomes ChIP-seq, 
and allows for genome wide functional analysis. Using this final method, binding 
sites of the protein of interest are sequenced and are associated with genes from 
numerous gene ontology databases using computer annotation tools. The wealth of 
these data is greatly untapped, and to repeat experiments when there is information 
available would prove to be wasteful and costly.  
A well-known repository for data sets from published papers is the National 
Center for Biotechnology Information’s Gene Expression Omnibus (GEO), online at 
http://www.ncbi.nlm.nih.gov/geo/, where array and sequenced based data are 
collected and can be searched for with keywords or an assigned accession number. 
New resources such as NURSA (Nuclear Receptor Signaling Atlas), online at 
http://www.nursa.org/, provide a way for researchers to seek specifically for 
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information pertaining to specific nuclear hormone receptors, with raw information 
organized by target rather than a massive repository to comb through.  
In relation to Dax-1, a search through GEO yielded both ChIP-chip and ChIP-
seq experiment results in mESC, the latter of which was obtained for further 
analysis [93]. The outcome of this analysis can be used not just to validate earlier 
studies in pluripotency, which were limited to a small set of genes in a PCR array, 
but also allows for new characterization of Dax-1 in mouse embryonic stem cells. 
The raw ChIP-seq data and other types of sequence data can be mapped onto the 
mouse genome through the use of computer annotation tools. These tools associate 
given sequences (also referred henceforth as peaks) where the protein of interest 
was bound to the regulatory regions of genes and calculate how accurate the 
enrichment of a set of genomic regions is. There are numerous gene annotation 
tools that use different types of statistical methods, genome databases, and gene 
ontology databases to map provided sequence data.  
Like humans, the mouse genome is comprised of only ~5% protein-coding 
regions, with the remainder “non-coding” DNA consisting of untranslated regions 
with unknown purpose, non-protein-coding genes, chromosomal structural 
elements, and regulatory sections [94]. Depending on the means of statistical 
analysis, there is a possibility for a false association when a test allows for an 
extensive regulatory region to be associated with a gene. These regions are also 
known as “gene deserts”, and depending on the database, can be as large as a million 
base pairs away from a gene. 
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Statistical Analysis 
The hypergeometric method is a standard gene enrichment test used by 
annotation tools such as DAVID and GO Term Finder. The formula, as shown in 
Figure 5-1A, tests if a gene with a number of peaks in an associated region is 
enriched with annotations out of a full set of genes in a genome. The values from the 
formula are as follows: N for the number of genes in the genome, n for the number 
of genes in a test gene set, Kπ for the number of genes in the genome with the 
annotation π, and kπ for the number of genes in a test gene set with annotation π. 
The p-value calculated by this method, using the formula in Figure 5-1A, is the 
probability of choosing kπ or more genes with annotation π when n genes are 
randomly selected from the genome. There is a heavy bias in this method to only 
associate peaks with genes if it falls in a proximal region, so many distal association 
are missed. 
The binomial method is another means of statistical analysis. Genes are 
assigned various regulatory region size, and the p value calculated in the formula in 
Figure 5-1B accounts for the probability of given peaks to fall within the range of 
numerous regulatory regions. This can provide novel gene associations, but this bias 
towards distal binding peaks can lead to false links. 
GREAT, which stands for genomic regions enrichment of annotations tool, is 
an annotation tool available online at (http://bejerano.stanford.edu/great/public-
2.0.2/html/) [95]. Running initial data through GREAT analysis provides the user 
with various calculated values from each statistical method. Among these values, 
there is a false discovery rate (FDR) q-value, which is obtained by selecting for an 
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ideal p-value among results. These corrected values account for false reads from a 
single method and give a more accurate ranking of the strength of gene association.  
In order to overcome the errors that come from each individual test even 
after correcting for possible false reads, provided data from GREAT are further 
processed to find ontology terms that are significant by both tests (B ∩ H). The 
extracted information is processed through R, a computer language and software 
environment useful for overall data analysis and graphics [96]. Users can process 
information through their own programming, or using available packages to 
implement statistical techniques.  
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Figure 5-1. Statistical analysis of ChIP-seq data using the GREAT online 
annotation software.  This software utilizes the formula of two tests, A. 
hypergeometric and B. binomial. C. GREAT carries out each method separately in 
order to associate a genomic peak or number of peaks with a single gene, obtained 
from an ontology annotation [97].   
 
  
 113 
Materials and Methods 
 
In collaboration with Vaishali Chaudhuri, a student enrolled in HS617 
(Projects in Statistical Computer for Biomedical Data Analytics) at the University of 
San Francisco, publically available data of Dax-1 ChIP-seq data on NCBI’s Gene 
Expression Omnibus (GEO) database were analyzed.  Data sets associated ascension 
numbers GSM1183116 and GSM1183117 pertaining to Dax-1 binding events in J1 
mouse embryonic stem cells were used [93]. The available data online are in .wig 
format, which is an older format containing data such as GC percent, probability 
scores, and transcriptome data. BED files of the replicate experiments carried out 
encoding detected Dax-1 peaks for the entire mouse genome was provided by the 
Kim lab at UT Austin.   
Analysis was carried out using the GREAT annotation tool, available online at 
(http://bejerano.stanford.edu/great/public-2.0.2/html/), where the data are 
provided as a BED file for input. The program associates the provided sequences 
with regulatory regions of genes, both proximal and distal, using numerous gene 
ontology databases and the two distinct statistical methods described in the 
background section. GREAT version 3.0.0 was used to analyze the Dax-1 ChIP-seq 
data from both BED files with parameters listed in Table 5-1, in order to find the 
association of provided peaks with gene ontologies. 
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Table 5-1. Parameters for GREAT version 3.0.0 online analysis. 
Species Assembly Mouse: NCBI build 38 (UCSC mm10, Dec/2011) 
Test regions DAX_BED1, DAX_BED2 [93] 
Background Regions Whole Genome 
Association rule settings Basal plus extension 
Proximal: 5.0 kb upsteam, 1.0 kb downstream 
Distal: 1000.0 kb 
 
The GREAT website then gives an output of associated genes grouped by the 
different gene ontologies, ranked by the calculated enrichment through both the 
binomial test and hypergeometric test. The results from the selected ontologies, as 
shown in Figure 5-2 were compiled from individual .tsv files into a single .csv file. 
This output was then run through three distinct packages in the R-language 
program: hierarchial cluster analysis [98], K means cluster analysis through ggplot 
[99], and principal component analysis [100]. 
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Figure 5-2. Selected Ontology results from processing DAX1_BED1 file through 
the online GREAT program. 
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Results 
 Following processing through the R programming language, the top five 
ontologies were selected for further analysis (Figure 5-3). These ontologies had high 
p-values in both statistical methods, and therefore show the greatest confidence of 
Dax-1 influence within the category. The overall descriptions of associated 
ontologies are described in Table 5-2. The highest ranking ontology encompasses 
genes that are expressed in differentiated cells that are part of the trophectoderm, 
followed by genes that lose their expression before birth or at birth, once the 
embryo no longer needs to develop. The next three categories are more broad, with 
two (Gen_V6.5 and Gen J1) containing genes that were down-regulated in late stages 
of differentiation in two distinct mouse embryonic stem cell lines, and one involving 
genes that participate in the platelet-derived growth factor receptor signaling 
pathway. 
 The genes within the selected ontologies were further narrowed down in 
Table 5-3 based on the distance of Dax-1 binding from the transcription start site 
(TSS). Genes were arbitrarily selected if the binding occurred within 6,000 base 
pairs before the start sites, and up to 2,000 base pairs after the start site. Genes that 
were previously studied in Chapter 4 and that appeared within the top ontologies, 
namely Nanog, Pou5f1, SOX2, and T, were also selected in Table 5-4. 
  
 117 
 
 
 
 
 
Figure 5-3.  Top five interactions in Dax-1 ChIP-seq interactions obtained 
through analysis of ontology data from GREAT by Dynamic Tree Cut, ggplot2, 
and PCA packages in R language. Image generated by V. Chaudhuri. 
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Table 5-2.  Top five Interactions in Dax-1 ChIP-seq interactions. 
Rank Biological 
Process 
Description Regions Genes Ontology 
Source 
1 TS5_Troph
ectoderm 
These genes are 
expressed and play a role 
in differentiated cells that 
are part of the 
trophectoderm. 
205 63 MGI Expression: 
Detected 
2 TS5_EEC Extraembryonic 
components consist of 
genes that may be lost 
before birth or will be 
discarded at birth, or 
when the embryo 
becomes an independent 
organism. 
 
214 67 MGI Expression: 
Detected 
3 Gen_V6.5 Genes down-regulated 
during late stages of 
differentiation of 
embryoid bodies from 
V6.5 embryonic stem 
cells. 
203 83 MSigDB 
Oncogenic 
Signatures  
4 PDGFR Platelet-derived growth 
factor receptor signaling 
pathway; The series of 
molecular signals 
generated as a 
consequence of a platelet-
derived growth factor 
receptor binding to one 
of its physiological 
ligands.  
73 16 GO Biological 
Process  
5 Gen_J1 Genes down-regulated 
during late stages of 
differentiation of 
embryoid bodies from J1 
embryonic stem cells. 
196 82 MSigDB 
Oncogenic 
Signatures  
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Table 5-3. Selected genes from the top five ontologies. Regions with negative 
values are peaks before the gene transcription start site (TSS), and positive base 
pair values are distances after the gene TSS. Genes that showed Dax-1 peaks within 
6,000 base pairs before TSS and 2,000 base pairs after TSS are shown. 
Gene Region (bp) Ontology 
Acacb +1,355, +5,318 (5) Gen_J1 
Ankrd10 -5,182 (5) Gen_J1 
Atp1b1 -94,421, -92,777, -64,303, -60,187, -45,391, -
36,143, -25,414, -2,739, +12,409, +79,738, 
+81,235 
(2) EEC 
Avpi1 -7,164 (3) Gen_V6.5 
Bcl3 -798, +7,504 (3) Gen_V6.5 
Cbx7 -1,159, +27,487, +30,030 (3) Gen_V6.5 
Cdh1 -3,617, +3,593, +11,996 (2) EEC 
Csrnp1 -276, +25,671 (3) Gen_V6.5 
Dppa2 -1,381 (3) Gen_V6.5 
Dppa5a -6,686, -3,389, -1,095, +3,296, +7,485, +8,252 (2) EEC 
Dpys +893, +76,433 (5) Gen_J1 
Eras +1,451 (5) Gen_J1 
Etv4 -557, +7,171, +8,185, +12,655 (3) Gen_V6.5 
Fbxo15 -851 (3) Gen_V6.5 
Fgfr2 +1,368. +12,718, +14,001 (2) EEC 
Frs2 -3,980 (1) Trophectorderm, 
(2) EEC 
Gbx2 -2,861 (3) Gen_V6.5, (5) 
Gen_J1 
Gli2 -353,788, 351,438, -345,108, -294,626, -251,793, -
248,600, -112,886, -98,929, -94,242, -28,753, -
22,877, -1,856, +4,415, +69,593, +405,274, 
+410,581 
(3) Gen_V6.5, (5) 
Gen_J1 
Gpa33 -4,837, +5,088, +12,317 (3) Gen_V6.5 
Gtf2ird1 -71,300, +55, +11,081, +17,489, +116,355, 
+119,412, +123,640, +127,110 
(2) EEC 
Hspg2 -6,950, +1,653, +11,424, +20,048, +28,713 (2) EEC 
Icam1 -1,113 (3) Gen_V6.5, (5) 
Gen_J1 
Iqgap1 -40,825, -19,882, +163, +19,419, +56,666 (2) EEC 
Jam2 -4,230, +5,299 (3) Gen_V6.5, (5) 
Gen_J1 
Kank2 -409, +30,112 (2) EEC 
Kat2b -5,197 (3) Gen_V6.5 
Kat7 -2,063 (2) EEC 
Kdm5b -4,567, +3,786, +10,410 (2) EEC 
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Mras +1,698, +12,426, +16,551, +19,849, +45,946 (3) Gen_V6.5 
Msrb2 -70,042, +118, +9,270 (3) Gen_V6.5 
Mybl2 -22,846, -2,379, +12,610, +20,795 (2) EEC 
Myc -6,505, +24,556, +25,544, +107,426, +176,743, 
+973,579 
(3) Gen_V6.5 
Nanog -44,193, -17,124, -4,791, +34 (1) Trophectoderm, 
(2) EEC 
Notum -2,804 (3) Gen_V6.5, (5) 
Gen_J1 
Nr0b1 -4,311, +1,854 (3) Gen_V6.5, (5) 
Gen_J1 
Ntn1 -355, +6,644, +52,524 (5) Gen_J1 
Pcolce -2,199, +555 (3) Gen_V6.5, (5) 
Gen_J1 
Pdgfc -13,859, -3,326 (4) PDGFR 
Pdgfrb -2,085 (4) PDGFR 
Pou5f1 -20,232, -15,487, -3,252, -1,985, -994, -100 (1) Trophectorderm, 
(2) EEC 
Ppcs -295 (5) Gen_J1 
Prmt6 -495 (5) Gen_J1 
Rif1 -733 (1) Trophectorderm, 
(2) EEC 
Sall4 -86,804, -84,580, -74,561, -24,142, -19,141, -
12,691, -2,340, +2,037 
(2) EEC 
Sema4b -56,334, -611, +34,730 (3) Gen_V6.5 
Slc39a4 -798 (1) Trophectorderm, 
(2) EEC 
Slc4a3 +129, +55,687, +258,304, +390,568, +482,891 (5) Gen_J1 
Socs3 -6,503, -3,615, +6,947, +36,854, +80,486 (3) Gen_V6.5, (5) 
Gen_J1 
Sox13 -134,922, -99,881, -4,606, -3,529, +25,571 (1) Trophectorderm, 
(2) EEC 
Sox2 -3,574, +18,648, +85,086, +106,847, +108,032, 
+110,438, +111,406, +787,897 
(1) Trophectorderm, 
(2) EEC 
Spry4 -1,087, +25,127, +27,298, +79,109 (3) Gen_V6.5 
Syncrip -2,124 (5) Gen_J1 
T -19,833, -4,154 (1) Trophectorderm, 
(2) EEC 
Tcea3 -1,457 (1) Trophectorderm, 
(2) EEC, (3) 
Gen_V6.5, (5) Gen_J1 
Tcf15 -1,242, +34,026, +35,029, +35,952, +36,925, 
+46,163 
(3) Gen_V6.5, (5) 
Gen_J1 
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Tdgf1 -1,994 (5) Gen_J1 
Tet1 -1,158, +681, +1,996, +3,457 +6,027 (5) Gen_J1 
Tfap2c -53,052, -32,751, -28,800, -4,830, +27,812, 
+44,801, +64,252, +278,876, +322,038 
(1) Trophectorderm, 
(2) EEC 
Tmem79 -2,377 (3) Gen_V6.5 
Trh -2,924, -1,883 (5) Gen_J1 
Ttc39b -5,907, -4,517, +7,385 (3) Gen_V6.5 
Tubb2b -1,447, +20,578 (5) Gen_J1 
Tubb3 +923 (3) Gen_V6.5, (5) 
Gen_J1 
Vegfc -976 (5) Gen_J1 
Zbtb45 -4,675 (3) Gen_V6.5 
Zfp219 -1,921 (1) Trophectorderm, 
(2) EEC 
Zfp296 -1,463 (1) Trophectorderm, 
(2) EEC 
Zfp42 -26,631, -13,963, -140 (3) Gen_V6.5 
Zfp57 -6,871, +27 (3) Gen_V6.5 
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Table 5-4. Genes from the top five ontologies that overlap with mESC 
pluripotency project. Regions with negative values are peaks before the gene 
transcription start site (TSS), and positive base pair values are distances after the 
gene TSS. Possible significant sites that are within a reasonable distance from the 
TSS are underlined. 
Gene Region (bp) 
Nanog -44,193, -17,124, -4,791, +34 
Pou5f1 -20,232, -15,487, -3,252, -1,985, -994, -100 
SOX2 
-3,574, +18,648, +85,086, +106,847, +108,032, +110,438, +111,406, 
+787,897 
T -19,833, -4,154 
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Discussion 
Analyzing the results of ChIP-seq allowed for a greater understanding of the 
broad influence Dax-1 has within the mouse embryonic stem cell model. The 
presence of the Dax-1 protein in a regulatory region of a target gene reveals possible 
direct interactions and influence on transcription. The resulting gene list (Table 5-3) 
does not encompass all of the genes associated with Dax-1 binding within the 
selected ontologies, because the GREAT program allows for extremely distal 
binding. While distal binding accounts for more complex interactions, more 
proximal sites are ultimately easier to investigate and confidently draw any 
conclusions from. 
Overall, the results shed some light on why Dax-1 appears to have a strong 
but not absolute influence on pluripotency. While it has some interactions with 
master regulators, it also appears to affect a subset of genes involved in a specific 
differentiation route towards maturation into the trophectoderm. Genes involved 
with development of the trophectoderm are among the first to be activated, since 
these cells are required for implantation of the embryo and eventually give rise to 
some of the placenta [101]. Therefore, modification of Dax-1 seems to heavily 
influence only one route, and other cells with transcription factors favoring any 
other route of differentiation may be less influenced by the Dax-1 absence. 
While the genes investigated in Chapter 4 were selected from previous 
research, they were but a small number out of the total number of identified 
interactions. Cross-referencing of candidate genes with the targets found through 
ChIP-seq analysis made up for the lack of labor-intensive ChIP experiments for each 
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individual gene. Among the candidates from Chapter 4, Dax-1 was found to be 
present within the regulatory regions of Nanog, Pou5f1 (aka OCT3/4), Sox2, and T 
(Table 5-4).  
Lastly, there are genes that were not previously identified as candidate 
targets through any previous array or project. There are those that fall within the 
realm of pluripotency and expand on the interactions within that phenomenon in 
stem cells, but additional ontologies available through the GREAT program revealed 
Dax-1 interactions with genes involved in a range of diseases. Manipulation of the 
statistical analyses can account for similar ontologies with great overlap of genes, 
and allow for different ontologies to gain a higher relative rank. Given that the 
mouse model is often used to further understand human models, interactions with 
possible novel genes can answer a myriad of questions. 
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End Summary 
 DAX-1 serves as a great protein of interest, with unique properties as an 
orphan nuclear hormone receptor. Its specific expression in cell types, especially 
stem cells and certain cancer cells, gives rise to questions about what molecular 
pathways in which it could possibly be involved.  
These interactions were investigated in a human model with two types of 
breast cells by changing the endogenous expression of DAX-1, based on studies that 
revealed DAX-1 involvement in cell survival pathways. Apoptosis appeared to be the 
process of interest, due to changes in key genes and a similar result to that of a 
known small molecular inhibitor treatment.  Following qPCR assays to observe 
mirrored expression in cell culture models that were treated to have opposing 
expression of DAX-1, candidate genes were selected for further analysis. BCL-2, an 
anti-apoptotic member of the BCL-2 protein family, was found to have DAX-1 
present along its promoter, and it is likely that this regulation is through interaction 
with ERα. Therefore, one way that DAX-1 influences apoptosis is through BCL-2 
transcriptional regulation. 
 In mouse embryonic stem cells, Dax-1 had been found to play a role in 
pluripotency. Using two different knock-down methods, siRNA and CRISPR-Cas9, 
candidate genes selected from earlier studies within the Tzagarakis-Foster Lab were 
tested for changes in gene expression. With the exception of the T gene, changes in 
expression for both types of knock-down treatments were similar and strongly 
suggested that Dax-1 interacts with subsets of genes involved in specific 
differentiation pathways.  
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 And lastly, the scope of Dax-1 regulated genes was expanded through 
statistical analysis of available Dax-1 ChIP-seq data, using the R-language and 
various packages to manipulate data. After first being run through an online 
program GREAT to find ontologies that are statistically significant through two 
analysis methods, binomial and hypergeometric, the results from each method were 
further processed to find overlapping results to confirm Dax-1 association. Resulting 
genes reveal interactions with not only candidate genes from small scale 
experiments, but also open up studies for uninvestigated and novel Dax-1 
transcriptional interactions. 
 Based on these results, DAX-1 is not limited to involvement with a single 
biological process, but is restricted enough to be a therapeutic target in an 
individual cell type. Apoptotic observations in the human breast cells were not seen 
in the mouse embryonic stem cells, and vice versa. The interactions within the 
breast cancer cells, not only with ERα but other key steroid receptors such as AR 
[102], strongly connect DAX-1 as a gene target within cancer.  DAX-1 and other 
orphan nuclear hormone receptors are increasingly becoming not just therapeutic 
targets [103], but also markers of prognosis and how successful therapy is [104]. 
Hopefully, these findings add to the rich story that continues to develop in the DAX-
1 related research field.  
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